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ABSTRACT 
Androgen receptor (AR) signaling is crucial to the development, growth, and homeostasis 
of the prostate gland, and its dysregulation mediates common prostate pathologies, including 
benign and malignant forms of neoplasia. Prostate cancer is the second most prevalent cancer 
and the sixth leading cause of cancer mortality in men. The mechanisms whereby AR regulates 
growth suppression and survival/death of luminal epithelial cells in the prostate gland and 
proliferation of malignant versions of these cells are not well understood, though they are central 
to prostate growth, homeostasis, and neoplasia. We hypothesized that in normal adult prostate, 
AR signaling may serve homeostatic roles in the regulation of cell cycle progression and 
programmed cell death such that it restrains the growth of healthy epithelial cells and accelerates 
the turnover of damaged epithelial cells. To test this hypothesis, we examined the 
growth/apoptosis response of human prostate epithelial cell lines (HPr-1AR, RWPE-AR and 
PC3-Lenti-AR) under optimized or stressed conditions, identified androgen-responsive genes 
that restrain cell cycle progression or mediate programmed cell death, and defined mechanisms 
whereby AR regulates their expression. Here, we report the mechanisms of AR-mediated growth 
suppression and AR-sensitized apoptotic cell death in these prostate epithelial cell lines. 
Under optimized culture conditions, AR signaling inhibits the proliferation of HPr-1AR 
and PC3-Lenti-AR cells, but does not induce cell death. AR-mediated growth suppression is 
dependent on the inhibition of cyclin D-CDK4/6 complexes through transcriptional repression of 
the CDK4 and CDK6 genes and transcriptional activation of the CDKN1A/p21 gene. Further, 
AR inhibits cyclin D2 transcription and destabilizes cyclin D1 mRNA in HPr-1AR cells. The 
decreased expression and activity of cyclin D-CDK4/6 complexes lead to a prolonged G0/G1 
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interval and, therefore, restrains cell cycle progression and proliferation of HPr-1AR and PC3-
Lenti-AR. 
Under stressed culture conditions, AR signaling sensitizes HPr-1AR and RWPE-AR cells 
to apoptotic cell death. Co-treatment of these cells with androgen and a cell stress agent, such as 
staurosporine (STS) or TNFα, synergistically increases apoptotic cell death in comparison to 
treatment with cell stress agent alone. The synergy between androgen and stress inducer is 
dependent on AR and transcription and involves the activation of the intrinsic mitochondrial 
apoptotic pathway. Expression analyses reveal that pro-apoptotic genes (BCL2L11/BIM, BOK 
and AIFM2) are androgen-induced, whereas pro-survival genes (BCL2L1/BCL-XL and MCL1) 
are androgen-repressed. Hence, we propose that the net effect of these AR-mediated expression 
changes shifts the balance of BCL2-family proteins in a manner that sensitizes mitochondria to 
apoptotic signaling and thus renders HPr-1AR more vulnerable to cell stress agents. These 
studies provide novel insights into the homeostatic roles of AR in the regulation of prostate 
epithelial cell proliferation and turnover. 
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Chapter 1 
Introduction 
Androgen receptor signaling 
Androgen action regulates the processes of sexual differentiation, spermatogenesis, 
pubertal maturation, and sex organ homeostasis in males [1-5]. Dysregulation of the androgen 
signaling are linked to a number of diseases, including spinal and bulbar muscular atrophy, 
androgen insensitivity syndrome and prostate neoplastic diseases. In humans and rodents the 
most potent endogenous androgens include testosterone and 5α-dihydrotestosterone (DHT). 
Testosterone is biosynthesized in the testis, where it acts locally, and it is released into the 
circulatory system. Additional target tissues that express the 5α-reductase enzyme, such as the 
prostate gland, convert the circulated testosterone into the more potent androgen, DHT [6,7]. The 
effects of androgens are mediated by the androgen receptor (AR), a 110 kDa nuclear receptor, 
which regulates the expression of androgen-responsive genes by multiple mechanisms [8-10]. In 
the absence of ligand, AR is thought to be inactive and sequestered in an aporeceptor complex of 
heat shock, chaperone and co-chaperone proteins, including HSP90, HSP70 and p23 [11,12]. 
Upon binding to agonistic ligands, such as testosterone and DHT, the predominantly cytosolic 
AR undergoes a change in conformation, dissociates from heat shock proteins, and accumulates 
in the nucleus, where AR associates with specific DNA sequences, recruits co-regulatory 
proteins and chromatin remodeling proteins, and thus regulates the transcription of target genes 
(Fig. 1.1) [13-17]. 
The androgen receptor, also known as NR3C4, belongs to the nuclear receptor 
superfamily of transcriptional regulators [18]. The human AR gene, which is located on the X 
chromosome, contains eight exons that encode a protein with distinct functional domains that are 
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shared by most nuclear receptors [19-23]. Exon 1 encodes the amino-terminal domain (NTD), 
and exons 2-3 encode the DNA-binding domain (DBD), which is connected by a hinge region to 
the C-terminal ligand-binding domain (LBD), encoded by exons 4-8. In addition, the activation 
function (AF)-1 and AF-2 domains located within the NTD and the LBD, respectively, are 
required for optimal transcriptional activation by the receptor [2,4,9,24,25]. The absolute length 
of AR is known to vary in human cells due to differences in the lengths of the polyglutamine and 
polyglycine tracts in the NTD. The number of polyglutamine repeats has been negatively 
associated with the transcriptional activity of AR. The expanded polyglutamine repeats are 
associated with reduced sperm production, testicular atrophy and infertility, whereas the shorter 
polyglutamine repeats are linked to higher risk of benign prostate hyperplasia and prostate cancer 
[26-29]. 
The members of the nuclear receptor superfamily are thought to mediate transcriptional 
regulation by the recruitment of co-regulatory proteins, which interact with nuclear receptors and 
the transcriptional machinery in a manner that either activates transcription (co-activator) or 
represses transcription (co-repressor) of target gene promoters. More than 200 proteins have 
been reported to be AR co-regulators [30,31]. AR and its co-regulators mediate transcriptional 
regulation of genes through multiple mechanisms, including chromatin remodeling, recruitment 
of the RNA polymerase II holoenzyme, stabilization of ligand-bound AR complexes, etc. [8,32-
35]. In human and rodent cells, the AR DBD binds to consensus sequences in the elementary 
half-sites AGAACAnnnAGTACT of an androgen response element (ARE) [14,16,36-38], then 
recruits co-activator proteins as well as the RNA polymerase II transcriptional machinery, and 
thus increases the transcription rate of the target gene [15,16,39,40]. Presumably, AR interacts 
with co-repressor proteins and inhibit the expression of target genes, although AR-mediated 
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mechanisms of transcriptional repression are poorly defined [41]. Alternatively, AR may 
regulate co-regulator recruitment and transcription at target genes by binding to other 
transcription factors in a tethering mechanism, which does not require an AR binding site near 
the target gene [42]. Early studies assumed that AR binding sites were located in the proximal 
promoter regions of target genes. However, recent studies using genome-wide chromatin 
immunoprecipitation (ChIP) assays have identified AR binding sites in promoter-distal, intronic, 
and 3’-untranslated regions in addition to promoter-proximal regions of androgen-responsive 
genes [36-39,43]. The distal AR binding sites have been suggested to loop back and interact with 
the promoter-proximal regions through protein-protein interactions and therefore influence gene 
transcription [16,39]. 
In addition to the canonical AR signaling mechanism, which involves AR binding to the 
target genes in the nucleus, ligand-activated AR has been suggested to activate kinase signaling 
cascades, and thus mediates, so called, non-genomic signaling effects, which may influence gene 
expression without binding to target genes in the nucleus [31,44]. Accumulating evidence 
indicates that activated AR can interact with signaling molecules at the cell membrane. Multiple 
signaling cascades, including ERK, PI3K, AKT, PKA, PKC, insulin-like growth factor 1 (IGF-1) 
and epidermal growth factor (EGF) pathways, have been shown to be activated by non-genomic 
AR signaling [45-47]. A distinguishing feature of non-genomic AR signaling is a rapid response, 
i.e., kinase signaling pathways are activated within seconds to minutes, in comparison to the 
slower kinetics of transcriptional regulation that are mediated by canonical AR signaling. 
Interestingly, following kinase activation, non-genomic AR signaling may feedback on AR and 
affect its expression, activity, localization or degradation. Hence, the AR-mediated genomic and 
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non-genomic signaling pathways are likely inter-linked and orchestrate normal gene regulatory 
functions [48-53]. 
 
Regulation of the cell cycle 
The growth and reproduction of eukaryotic life is dependent on the faithful duplication 
and distribution of chromosomes into daughter cells through a conservative mechanism called 
cell cycle [54]. Cell cycle, or cell division, was originally divided into two stages, mitosis (M) 
and interphase. Cells replicate their chromosomes during interphases, and they segregate the 
replicated chromosomes into daughter cells during M phases. M phase includes prophase, 
metaphase, anaphase and telophase [55]. Interphase is further divided into G1, S, and G2 phases 
when cells prepare for DNA synthesis (G1), replicate DNA (S) and prepare for mitosis (G2). 
Before commitment to DNA replication, G1 cells can enter a quiescent state called G0 and 
therefore stop growing and dividing (Fig. 1.2) [55,56]. 
The transitions through the various phases of the cell cycle are primarily regulated by 
cyclin-dependent kinases (CDK), a family of serine/threonine protein kinases that are activated 
temporally during cell cycle progression. CDK4, CDK6 and CDK2 are activated and drive the 
G1/S-phase transition, whereas CDK2 and CDK1 are more important for cell cycle progression 
in S phase and the G2/M-phase transition, respectively (Fig. 1.2). The expression of the CDK 
proteins is thought to remain relatively unchanged during the cell cycle, whereas the kinase 
activity of the CDKs is regulated periodically by cyclins [55,57,58]. Cyclin proteins are the 
regulatory subunits of the CDK complexes, and the expression of several cyclins (E, A or B-type 
but not D-type) is known to fluctuate during the cell cycle and alter the activity of the associated 
CDK complexes. The D-type cyclins (cyclin D1, D2 and D3) bind to CDK4 and CDK6 and form 
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complexes that are essential for entry into G1 phase [59]. Cyclin E associates with CDK2 and 
thus regulates the G1/S-phase transition [60]. The formation of cyclin A-CDK2 complexes is 
required for DNA replication during S phase [61,62]. Further, cyclin A also binds to CDK1 to 
promote entry into M, whereas cyclin B-CDK1 complexes regulate M-phase progression (Fig. 
1.2) [55,63,64]. In addition, cyclin H-CDK7 has been shown to activate CDK1, CDK2 and 
CDK4 complexes, and therefore may influence multiple cell cycle transitions [65]. 
The kinase activity of the CDKs can be inhibited by cell cycle inhibitory proteins (CDK 
inhibitors), which bind to CDKs alone or to the cyclin-CDK complexes, and suppress CDK 
activity (Fig. 1.2). There are two major families of CDK inhibitors, the INK4 family and 
CIP/KIP family [66]. The INK4 family proteins (CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, 
CDKN2C/INK4C/p18, CDKN2D/INK4D/p19) bind to CDK4/6 and block the formation of 
cyclin D-CDK4/6 complexes [67]. The CIP/KIP family proteins (CDKN1A/p21/Waf1/Cip1, 
CDKN1B/p27/Cip2, CDKN1C/p57/Kip2) inhibit the CDK4/6 and CDK2 complexes, and to a 
less extent, CDK1 complexes, therefore displaying selective inhibition of cell cycle progression 
in G1 and S phases[68-71]. 
Typically, cell proliferation is tightly associated with cell cycle regulation, and the cell 
cycle can be modulated at the restriction point and checkpoints, including the G1/S and G2/M 
checkpoints. The restriction point is defined as a threshold point in G1 phase after which the cell 
is irreversibly committed to enter the cell cycle and finish cell division. In addition to the 
restriction point, there are checkpoints to arrest the cell cycle in response to DNA damage and 
provide time for DNA repairs [55,72]. During cell cycle progression, the G1/S-phase transition is 
a rate-limiting step, and it marks the initiation of DNA synthesis and the commitment to cell 
division [73]. Cyclin D-CDK4/6 complexes and Cyclin E-CDK2 complexes play crucial roles in 
6 
the regulation of the G1/S-phase transition. Complexes containing cyclin D and CDK4/6 are 
known to phosphorylate retinoblastoma protein (RB). Phosphorylation of RB (p-RB) inhibits 
RB-E2F complex formation and thus relieves RB-mediated growth suppression and increases the 
expression of S phase promoting genes, including cyclin A, cyclin E, and Cdc25 [74-76]. Indeed, 
the regulation of cyclin D-CDK4/6 complexes is a common strategy through which many 
signaling pathways, including AR signaling, modulate G1/S-phase transition and therefore cell 
division. 
 
Regulation of apoptosis 
Programmed cell death is a homeostatic mechanism to maintain cell populations [77]. 
There are three major types of programmed cell death, including apoptosis (type I), autophagic 
cell death (type II), and necroptosis (type III). Apoptosis is the most studied and best understood 
form of programmed cell death. Apoptosis plays a fundamental role in regulating cell number 
and eliminating unwanted or potentially dangerous cells [78]. The hallmarks of apoptosis include 
nuclear shrinkage, chromatin condensation, DNA fragmentation, and apoptotic body formation 
[79-81]. A subset of the cysteine-dependent aspartate-specific proteases, known as caspases, 
plays a central role in these morphological changes by actively cleaving key target proteins. 
Autophagy is an evolutionarily conserved process that serves to maintain homeostatic cellular 
functions like protein degradation and organelle turnover. Autophagy is characterized by 
autophagosome formation, which serves to encapsulate cytoplasmic macromolecules and 
organelles in double membrane vesicles and breakdown of their content [82,83]. In general, 
autophagy plays a pro-survival role in the cellular stress response. However, excessive 
autophagy eventually leads to cell death in a mechanism different from apoptosis [84,85]. 
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Necroptosis, which shares certain morphological similarities to oncotic necrosis (e.g. swelling of 
the organelles and cell implosion), is also a strictly controlled process of cell death. Unlike 
apoptosis, necroptosis does not require the activation of caspases and is usually inhibited by 
apoptotic signaling pathways. Therefore, it is believed to be an alternative pathway to eliminate 
damaged cell when apoptotic signaling is suppressed [86-88]. 
The mechanisms of apoptosis have been deeply explored during the past two decades 
(Fig. 1.3). Dependent on the origin of the apoptotic signal, the mode of apoptosis is usually 
divided into two pathways, the extrinsic pathway and the intrinsic pathway. At the molecular 
level, these two pathways involve the activation of different caspase cascades. The caspase 
family is traditionally categorized into executor caspases and initiator caspases. Executor 
caspases are thought to execute apoptosis after they are proteolytic processed by initiator 
caspases [78,89,90]. In the extrinsic pathway, cell surface death receptors, including members of 
the tumor necrosis factor receptor superfamily, sense extracellular death ligands and activate 
death inducing signaling complexes, containing initiator caspase-8 or -10. The active initiator 
caspases further cleave and activate executor caspase-3, -6 or -7 [91-93]. In the intrinsic pathway, 
multiple stress signals (e.g. ATP depletion, DNA damage, endoplasmic-reticulum stress and 
growth factor deprivation), converge on mitochondria and increase mitochondrial outer 
membrane permeabilization (MOMP), which eventually leads to the release of pro-apoptotic 
factors such as cytochrome c, apoptosis-inducing factor mitochondrion-associated 1/2 (AIFM1/2) 
and IAP-binding mitochondrial protein (DIABLO). The release of cytochrome c promotes the 
formation of the apoptosome, which further activates initiator caspase-9 and ultimately executor 
capase-3, -6 or -7 [94-97]. 
8 
Mitochondria play a central role in the regulation of apoptosis. As the release of 
cytochrome c is crucial to apoptosome formation and activation of the intrinsic caspase cascade 
[94-97], the permeability of the outer mitochondrial membrane is tightly controlled. This is 
accomplished by B-cell CLL/lymphoma 2 (BCL2) family proteins [98]. The BCL2 protein 
family consists of three subfamilies, which are distinguished by the number of BCL2 homolog 
(BH) domains that they present. The pro-survival BCL2 subfamily (BCL2, BCL2L1/BCL2-XL, 
BCL2A1, myeloid cell leukemia 1 (MCL1), etc.) has a BH4 domain. The other two subfamilies 
are pro-apoptotic. They either lack a BH4 domain (BCL2-associated X protein (BAX) family) or 
only display a BH3 domain (BH3-only family) [78]. The BAX family proteins (BAX, BCL2-
antagonist/killer (BAK) and BCL2-related ovarian killer (BOK)) mainly function at the 
mitochondrial membrane. The oligomerization of BAX and BAK forms holes at the 
mitochondrial out membrane and thus increases MOMP and the release of cytochrome c [99]. 
The pro-survival BCL2 subfamily proteins interact with BAX family proteins, prevent hole 
formation, and therefore maintain mitochondrial membrane integrity [100]. The BH3-only 
family proteins (BH3 interacting domain death agonist (BID), BCL2-associated agonist of cell 
death (BAD), BCL2L11/BIM, phorbol-12-myristate-13-acetate-induced protein 1 
(PMAIP1/NOXA), BCL2 binding component 3 (BBC3/PUMA), etc.) interact with pro-survival 
BCL2 subfamily proteins and prevent them from interfering with BAX family proteins [99]. 
Hence, the stoichiometry of pro-survival and pro-apoptotic BCL2 family proteins determines the 
fate of a given cell [79,100]. Extrinsic pathway activation has also been shown to enhance 
MOMP through cleavage of pro-apoptotic BH3 interacting domain death agonist (BID) protein 
by initiator caspase-2 or -8. Hence, mitochondria indeed serve as hubs of intrinsic and extrinsic 
apoptotic signaling pathways [101-105]. 
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The paradoxical role of AR in prostate physiology and pathology 
The prostate is an exocrine gland in the male reproductive system that secretes alkaline 
prostatic fluid to protect spermatozoa and prolong their lifespan. It is also a primary target tissue 
of androgens. In humans and rodents, the prostate gland develops from the urogenital sinus 
(UGS) [106]. Androgen production by the testis activates AR in the outer mesenchymal layer of 
the UGS, known as the inductive urethral mesenchyme [107-110]. Androgen action in the 
inductive urethral mesenchyme has been suggested to induce formation of prostatic ductal buds 
in the urethral epithelium and their outgrowth through a paracrine signaling mechanism [111-
113]. In addition, AR signaling also stimulates the elongation of the fetal prostatic buds, 
perinatal branching morphogenesis and cytodifferentiation of the prostatic epithelium [111-115]. 
In humans, the normal adult prostate consists of a glandular epithelium surrounded by 
layers of fibromuscular stroma, and the prostatic epithelium can be further subdivided into basal 
and luminal layers. The stromal and luminal epithelial cells robustly express AR [116]. It has 
long been thought that the vast majority of cells in the basal layer, including intermediate cells, 
do not express AR. However, recent studies have shown that some basal and intermediate cells 
located in the basal layer indeed express AR [117-120]. Interestingly, AR exerts multiple 
functions in adult prostate homeostasis. Using AR-deficient mouse models, Wu et al. 
demonstrated that AR is necessary for differentiation and secretory function of the luminal 
epithelial cells in the prostate [119]. AR action in prostate stromal cells is thought to promote 
their secretion of growth and survival factors, which serve to enhance luminal epithelial cell 
survival [121]. Notably, the secretory luminal epithelial cells in the prostate robustly express AR. 
However, these cells are differentiated and quiescent, and AR activation does not stimulate the 
proliferation of these cells [122]. Meanwhile, AR signaling in basal epithelial cells has been 
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suggested to suppress proliferation and drive differentiation of some basal and intermediate cells 
[119,120]. Taken together, these studies suggest that AR signaling in normal adult prostate 
epithelium maintains the secretory function of the mature prostate gland by regulating a gene 
expression program that suppresses epithelial cell growth and proliferation and supports 
cytodifferentiation. 
In contrast to the AR-mediated growth suppression and differentiation of normal luminal 
epithelial cells, a critical transition occurs early in prostate cancer such that the growth and 
proliferation of malignant versions of these cells becomes dependent on AR [123]. Prostate 
cancer is the second most prevalent cancer and the sixth leading cause of cancer-related death 
among men in the United States [124]. The growth promoting effect of androgens in prostate 
cancer was brought to light more than 70 years ago by Huggins and Hodges, who pioneered the 
use of surgical castration and systemic androgen deprivation as therapeutics for prostate cancer 
[125]. Most prostate cancer cells express AR and are dependent on AR action for growth and 
proliferation [123,126-130]. Androgen deprivation therapy (ADT) remains the most effective 
therapy for metastatic prostate cancer, although it is not a cure. The blockade of androgen 
signaling induces apoptosis and suppresses the proliferation of prostate cancer cells, which is 
evidenced by tumor regression. However, as serum androgen levels drops, a subset of prostate 
cancer cells is able to adapt to castrate levels of androgens. Several adaptation mechanisms have 
been identified to potentiate AR signaling as a strategy to survive in the presence of castrate 
levels of androgen, including 1) AR gain-of-function mutation, 2) AR amplification, 3) 
expression of constitutively active AR splice variants, 4) crosstalk with other signaling pathways, 
and 5) altered interaction between AR and co-regulatory proteins [123,129,131]. These 
adaptations eventually lead to the development of castration-resistant prostate cancer (CRPC). 
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Notably, CRPC cells are still somewhat dependent on AR signaling for growth [128,130,132-
136]. The development of high-affinity AR antagonists and inhibitors of androgen biosynthesis 
has shown promising results in the treatment of CRPC patients [44,136-143]. Indeed, AR 
signaling influences the proliferation and survival of prostate cancer cells. 
Unlike the growth promoting effect of AR signaling in most prostate cancer-derived cells, 
AR signaling in non-malignant prostate epithelial cells may maintain their secretory function by 
regulating a gene expression program that suppresses epithelial cell growth and proliferation and 
supports cytodifferentiation. Hence, there is a homeostatic equilibrium that balances cell growth 
and division and cell death in a manner that opposes enlargement of the prostate gland. The 
molecular mechanisms whereby AR signaling regulates this equilibrium in non-malignant 
prostate epithelial cells is unknown. Answers to these questions will provide greater insights into 
the functional roles of AR signaling in normal prostate epithelium, and possibly reveal novel 
therapeutic targets for prostate cancer. In this thesis research, we explored these unknowns using 
in vitro cell culture systems. We investigated the mechanisms whereby AR signaling regulates 
growth suppression and the cellular stress response of human prostate epithelial cells in Chapter 
Two and Chapter Three, respectively. 
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Figures 
 
Fig. 1.1 A concise review for androgen receptor (AR) signaling pathway. 
The action of androgen is mediated by AR in the molecular and cellular level. Upon exposure to 
endogenous ligands, testosterone (T) or dihydrotestosterone (DHT), AR undergoes conformational 
changes, dissociates from chaperones (HSP) and relocates into the nucleus. The homo dimers of AR in 
the nucleus further bind to androgen response elements (ARE), recruit co-regulators and RNA polymerase 
II complexes and then mediate the expressions of androgen-responsive genes (ARG). Alternatively, active 
AR may also interact with other intracellular signaling (MAPK, AKT, PKC, mTOR, etc.) and therefore 
exert non-canonical functions which may or may not involve gene regulations. 
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Fig. 1.2 Molecular events of cell cycle. 
Briefly, cell cycle is divided into mitosis (M) and interphase. Cells replicate their chromosomes during 
interphases, and they segregate the replicated chromosomes into daughter cells during M phases. 
Interphase is further divided into G1, S, and G2 phases when cells prepare for DNA synthesis (G1), 
replicate DNA (S) and prepare for mitosis (G2). Before commitment to DNA replication, G1 cells can 
enter a quiescent state called G0 and therefore stop growing and dividing. The progression of cell cycle is 
primarily driven by multiple cyclin – cyclin-dependent kinase (CDK) complexes at different stages. The 
expression of the CDK proteins is thought to remain relatively unchanged during the cell cycle, whereas 
the kinase activity of the CDKs is regulated periodically by cyclins. The kinase activity of the CDKs can 
be inhibited by cell cycle inhibitory proteins (CDK inhibitors), which bind to CDKs alone (INF4 family 
proteins) or to the cyclin-CDK complexes (CIP/KIP family proteins), and suppress CDK activity. 
Typically, cell proliferation is tightly associated with cell cycle regulation, and the cell cycle can be 
modulated at the restriction point and checkpoints, among which the G1/S-phase transition is tightly 
regulated as a rate-limiting step. 
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Fig. 1.3 Molecular events of apoptosis. 
Apoptosis plays a central role in regulating cell number and eliminating unwanted cells. The hallmarks of 
apoptosis include caspase activation, chromatin condensation, DNA fragmentation, nuclear shrinkage and 
apoptotic body formation. Dependent on the origin of the apoptotic signal (extrinsic or intrinsic), different 
caspase cascades are activated. In the extrinsic pathway, cell surface death receptors sense extracellular 
death ligands and activate death inducing signaling complexes, containing initiator caspase-8 or -10. The 
active initiator caspases further cleave and activate executor caspase-3, -6 or -7. In the intrinsic pathway, 
multiple stress signals converge on mitochondria and increase mitochondrial outer membrane 
permeabilization (MOMP) and eventually the release of pro-apoptotic factors (cytochrome c (CYCS), 
apoptosis-inducing factor mitochondrion-associated 1/2 (AIFM) and IAP-binding mitochondrial protein 
(DIABLO)). The release of cytochrome c promotes the formation of the apoptosome, which further 
activates initiator caspase-9 and ultimately executor caspase-3, -6 or -7. BCL2 family proteins play 
central roles in the regulation of mitochondrial membrane permeability. The pro-apoptotic BCL2 family 
genes (BAX, BAK, BOK, BIM, etc.) facilitate the formation of pore complexes on the mitochondrial 
membrane, leading to MOMP, whereas the pro-survival BCL2 family genes (BCL2, BCL-XL, MCL1,  
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Fig. 1.3 (cont.) 
etc.) inhibit this process. The activation of caspase-2 or -8 has also been shown to enhance MOMP 
through cleavage of pro-apoptotic BID protein. Hence, mitochondria serve as the hub where both intrinsic 
and extrinsic apoptotic pathways merge. 
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Chapter 2 
Androgen Receptor-Mediated Growth Suppression of HPr-1AR and 
PC3-Lenti-AR Prostate Epithelial Cells 
Abstract 
The androgen receptor (AR) mediates the developmental, physiologic, and pathologic 
effects of androgens including 5α-dihydrotestosterone (DHT). However, the mechanisms 
whereby AR regulates growth suppression and differentiation of luminal epithelial cells in the 
prostate gland and proliferation of malignant versions of these cells are not well understood, 
though they are central to prostate development, homeostasis, and neoplasia. Here, we identify 
androgen-responsive genes that restrain cell cycle progression and proliferation of human 
prostate epithelial cell lines (HPr-1AR and PC3-Lenti-AR), and we investigate the mechanisms 
through which AR regulates their expression. DHT inhibited proliferation of HPr-1AR and PC3-
Lenti-AR, and cell cycle analysis revealed a prolonged G1 interval. In the cell cycle, the G1/S-
phase transition is initiated by the activity of cyclin D and cyclin-dependent kinase (CDK) 
complexes, which relieve growth suppression. In HPr-1AR, cyclin D1/2 and CDK4/6 mRNAs 
were androgen-repressed, whereas CDK inhibitor, CDKN1A, mRNA was androgen-induced. 
The regulation of these transcripts was AR-dependent, and involved multiple mechanisms. 
Similar AR-mediated down-regulation of CDK4/6 mRNAs and up-regulation of CDKN1A 
mRNA occurred in PC3-Lenti-AR. Further, CDK4/6 overexpression suppressed DHT-inhibited 
cell cycle progression and proliferation of HPr-1AR and PC3-Lenti-AR, whereas CDKN1A 
overexpression induced cell cycle arrest. We therefore propose that AR-mediated growth 
suppression of HPr-1AR involves cyclin D1 mRNA decay, transcriptional repression of cyclin 
D2 and CDK4/6, and transcriptional activation of CDKN1A, which serve to decrease CDK4/6 
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activity. AR-mediated inhibition of PC3-Lenti-AR proliferation occurs through a similar 
mechanism, albeit without down-regulation of cyclin D. Our findings provide insight into AR-
mediated regulation of prostate epithelial cell proliferation. 
 
Introduction 
Prostate cancer is the second most prevalent cancer and the sixth leading cause of cancer 
mortality in men [124]. Most prostate cancer cells express the androgen receptor (AR) and are 
dependent on AR action for growth and proliferation [123,126-130,144]. Androgen ablation, 
through suppression of androgen biosynthesis and/or antagonism of AR activity, initially induces 
apoptosis in a subset of prostate cancer cells and suppresses growth and proliferation in those 
that survive, which is evidenced by tumor regression and subsequent regrowth [127,131,145-
147]. Indeed, the proliferative actions of androgen-activated AR are well known in the mature 
prostate, although they are unique to neoplastic cells in this exocrine gland. However, an early 
event that is common among prostate cancers is a transition from AR-mediated growth 
suppression and differentiation of luminal epithelial cells to AR-mediated growth and 
proliferation of malignant versions of these cells [123]. 
Interestingly, the antiproliferative actions of androgen-activated AR in normal prostatic 
epithelia have also been demonstrated in vivo and in several cellular contexts. In humans and 
rodents, the prostatic epithelium contains basal and luminal layers interspersed with rare 
neuroendocrine cells. Mice lacking epithelial AR in the mature prostate develop prostate tissue 
that is hyperproliferative and less differentiated compared to wild-type littermates [119,120]. It 
has long been thought that the vast majority of cells in the basal layer, including intermediate 
cells, do not express AR. However, AR localization in a subset of basal cells has been reported 
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for normal and hyperplastic prostate samples, and mounting evidence indicates that intermediate 
cells located within the basal layer, indeed, express AR [117-120]. In addition, compelling 
experiments in AR knockout mice have demonstrated that AR expression in intermediate cells is 
necessary for growth suppression and differentiation of these cells into luminal epithelial cells 
[119,120]. The proliferation and survival of intermediate cells in the basal layer are also thought 
to be regulated by AR-dependent signaling in prostate stroma and subsequent paracrine signaling 
mediated by growth and survival factors, known as andromedins, although a true andromedin 
remains to be identified [119,120,148-155]. Eventually, the intermediate cells migrate to the 
luminal layer, where AR expression is abundant [156,157]. In these cells, the activation of AR 
by physiologic ligands such as 5α-dihydrotestosterone (DHT) is thought to activate a gene 
program that suppresses proliferation and induces differentiation of intermediate cells to luminal 
epithelial cells that carryout secretory functions [149,158,159]. However, the mechanism 
whereby AR restrains cell proliferation of prostate epithelial cells is not understood. 
Typically, cell proliferation is tightly associated with cell cycle regulation, and the cell 
cycle can be modulated at checkpoints, including the G1/S- and G2/M-phase transitions [160]. 
The G1/S-phase transition is a rate-limiting step in cell cycle regulation, and it marks the 
initiation of DNA synthesis, which represents commitment to the division of the parental cell 
into two daughter cells [73]. As a central regulator of the G1/S-phase transition, cyclin D 
expression is highly regulated such that its expression peaks in G1 phase. Cyclin D stimulates the 
G1/S-phase transition through association with and stabilization of cyclin-dependent kinases 
(CDK) 4 or 6 (CDK4/6), which are inhibited by CDK inhibitors, including CDKN1A/p21 and 
CDKN1B/p27 [161-163]. Complexes containing cyclin D and CDK4/6 (cyclin D-CDK4/6) are 
known to phosphorylate retinoblastoma protein (RB). Phosphorylation of RB (p-RB) inhibits 
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RB-E2F complex formation and thus relieves RB-mediated growth suppression and increases 
expression of S phase promoting genes, including cyclin A [76,164]. 
Androgen activation of stably expressed AR has been shown to inhibit the proliferation 
of HPr-1 immortalized human prostate epithelial cells, HPrE human prostate basal epithelial 
cells, mPrE mouse prostate basal epithelial cells, and PC-3 prostate cancer cells [120,154,165-
169]. Androgen also inhibits the proliferation of MCF-7 breast cancer cells, which are known to 
express AR [170]. In a previous study, we identified androgen responsive genes (ARGs) in HPr-
1AR human prostate epithelial cells, and several of these ARGs were implicated in negative 
regulation of cell proliferation and progression through the cell cycle [36]. Based on these 
previous findings, we hypothesized that androgens and AR signaling may serve a specific role in 
cell cycle regulation that restrains the proliferation of prostate epithelial cells. We explore this 
hypothesis in the present study. 
Here, we identify ARGs in prostate epithelial cells that control cell cycle progression and 
proliferation and investigate the mechanisms through which AR regulates their expression. We 
have dissected androgen action on the G1/S-phase transition of the cell cycle in HPr-1AR human 
prostate epithelial cells and PC3-Lenti-AR prostate cancer cells. We found that AR-mediated 
down-regulation of cyclin D-CDK4/6 complexes in both cell lines decreased RB 
phosphorylation and inhibited the G1/S-phase transition in the cell cycle, reducing cell 
proliferation. In HPr-1AR, AR-mediated growth suppression involves down-regulation of cyclin 
D-CDK complexes through transcriptional repression of cyclin D2, CDK4, and CDK6 mRNAs, 
destabilization of cyclin D1 mRNA, and transcriptional activation of CDKN1A. In PC3-Lenti-
AR, the mechanism is limited to AR-mediated transcriptional regulation of CDK4, CDK6, and 
CDKN1A expression. Furthermore, overexpression of CDK4 or CDK6 suppressed DHT-
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inhibited cell cycle progression and proliferation in HPr-1AR and PC3-Lenti-AR, whereas 
CDKN1A overexpression induced cell cycle arrest in these prostate cell lines. Taken together, 
these data support the hypothesis that AR signaling normally functions to restrain prostate 
epithelial cell proliferation through cell cycle regulation. 
 
Materials and Methods 
Cell culture, plasmids, transfection, and viral transduction 
HPr-1 cells and HPr-1AR cells were grown as described [36,165] in keratinocyte serum 
free medium (17005-042, Invitrogen, Carlsbad, CA) without androgen supplementation. PC-3 
cells and PC3-Lenti-AR cells were grown as described [154] in RPMI Medium 1640 (11835-
055, Invitrogen) with 10% fetal bovine serum (FB-11, Omega Scientific, Tarzana, CA) that was 
treated with charcoal-dextran to deplete steroids. HEK 293FT cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM, 10-017-CV, Mediatech, Manassas, VA) with 10% fetal 
bovine serum, 1 mM MEM sodium pyruvate (25-000-CI, Mediatech) and 500 μg/mL Geneticin 
(G418, 10131-035, Invitrogen). All cells were grown in a humidified 5% CO2 atmosphere at 
37°C. Cells were treated in growth media with 0-10 nM AR agonist (5α-dihydrotestosterone, 
DHT) or 10 μM AR antagonist (2-hydroxyflutamide, OHF) for the indicated duration. In 
competition experiments, cells were cotreated with 1 nM DHT and 10 μM OHF for the indicated 
duration. In RNA destabilization and degradation experiments, transcription was inhibited 1 hour 
prior to DHT or vehicle control treatment using 1 μg/ml actinomycin D (ActD, A1410, Sigma-
Aldrich, St. Louis, MO) or 20 μg/ml 5,6-dichlororibofuranosylbenzimidazole (DRB, D1916, 
Sigma-Aldrich). 
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For transient overexpression of cyclin D1 and cyclin D2, control vector pBEC118 was 
generated by insertion of an EcoR I - Bbs I fragment, which contains multiple cloning sites and 
an internal ribosome entry sequence followed by the coding sequence of the enhanced green 
fluorescent protein (GFP), into CSII-EF-MCS (RIKEN BioResource Center). Full-length cyclin 
D1 and D2 protein coding regions were amplified from HPr-1AR cDNA using PCR, and they 
were inserted into the EcoR I and Xho I sites of pBEC118, generating pBEC125 (CCND1) and 
pBEC126 (CCND2). All constructs were amplified in Stbl3 E. coli (C7373-03, Invitrogen) and 
transfected into HPr-1AR using Novagen GeneJuice Transfection Reagent (70967-3, EMD 
Millipore, Billerica, MA). The pBEC118-based vectors express enhanced green fluorescent 
protein (GFP), which allowed for gating and analysis of transfected cells among a background of 
untransfected cells. 
For stable overexpression of CDK4, CDK6, and CDKN1A using lentiviral transduction, 
control vector pBEC127 was generated by insertion of an EcoR I - Pme I fragment, which 
contains multiple cloning sites and an internal ribosome entry sequence followed by the coding 
sequence of the monomeric red fluorescent protein (RFP), into CSII-EF-MCS (RIKEN 
BioResource Center). Full-length CDK4, CDK6, and CDKN1A protein coding regions were 
amplified from HPr-1AR cDNA or OriGene cDNA clones (OriGene Technologies, Rockville, 
MD) using PCR, and they were inserted into the EcoR I and BamH I sites of pBEC127, 
generating pBEC128 (CDK4), pBEC129 (CDK6), and pBEC130 (CDKN1A). The pBEC127-
based expression vectors were amplified in Stbl3 E. coli (C7373-03, Invitrogen), transfected into 
HEK 293FT cells for lentivirus production, and transduced into HPr-1AR and PC3-Lenti-AR 
cells using pseudotyped lentivirus. The pBEC127-based vectors express monomeric red 
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fluorescent protein (RFP), which allowed for sorting, gating, and analysis of transduced cells 
among a background of untransduced cells. 
Briefly, HEK 293FT cells at 90-95% confluence in culture medium lacking G418 on 10-
cm tissue culture dishes were cotransfected with a pBEC127-based expression vector and viral 
packaging vectors, which express the VSV-G, REV, GAG, and POL proteins using 
Lipofectamine 2000 Reagent (11668-019, Invitrogen). Culture medium lacking G418 was 
refreshed 12 hours after transfection. After 36 hours, the culture medium containing pseudotyped 
lentivirus was collected, and cell debris was removed by centrifugation at 1000×g for 15 min and 
filtration through a Millex-HV 0.45 μm PVDF membrane (SLHV033RS, EMD Millipore). 
Psedotyped lentiviruses were concentrated using polyethylene glycol precipitation [171]. Virus-
containing supernatant was incubated with 8.5% polyethylene glycol 6000 (81260, Sigma-
Aldrich) and 0.3 M NaCl at 4°C for 4 hours. Lentivirus was collected by centrifugation at 
3000×g for 30 min, resuspended in PBS, and stored at -80 °C. To generate stable cell lines 
overexpressing CDK4, CDK6, or CDKN1A proteins and RFP control protein, HPr-1AR and 
PC3-Lenti-AR cells were incubated with the corresponding lentivirus concentrate and 10 μg/mL 
polybrene (H9268, Sigma-Aldrich) to achieve infection efficiency ≥80%. Virus-infected cells 
were amplified for 1-2 weeks prior to cell sorting. For stable overexpression lines, 300,000 or 
more RFP-positive cells were sorted and collected using a FACSAria II cell sorter (Becton 
Dickinson Biosciences, Franklin Lakes, NJ). Sorted cells were amplified for two additional 
weeks, and the expression of the RFP, CDK4, and CDK6 proteins was validated using 
fluorescence microscopy and immunoblot analysis.  
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Cell proliferation, apoptosis, and cell cycle analysis 
The relative number of viable cells in culture was determined by quantification of ATP in 
metabolically active cells using CellTiter-Glo Luminescent Cell Viability Assay Kit (G7571, 
Promega, Madison, WI). Briefly, cells were exposed to 50% CellTiter-Glo Reagent in PBS and 
luminescence was analyzed using a VICTOR X5 plate reader (2030-0050, PerkinElmer, 
Waltham, MA). 
Apoptotic cell death was assessed by flow cytometry using the Annexin V/Dead Cell 
Apoptosis Kit with Alexa Fluor 488-conjugated annexin V and PI for Flow Cytometry (A13201, 
Molecular Probes, Grand Island, NY). Briefly, cells were exposed, according to the 
manufacturer’s instruction, to Alexa Fluor 488-conjugated annexin V protein (annexin V), which 
binds with high affinity to phosphatidylserine, and propidium iodide (PI) nucleic acid binding 
dye. Cells were analyzed using an LSR II flow cytometer (Becton Dickinson Biosciences, 
Franklin Lakes, NJ) with FCS Express 4 Flow Cytometry software (De Novo Software, 
Glendale, CA). The percentages of cells undergoing apoptosis were determined by dual color 
analysis, which allowed us to distinguish three subsets of cells: viable cells (annexin V-negative 
and PI-negative), early apoptotic cells (annexin V-positive and PI-negative), and late apoptotic or 
necrotic cells (annexin V-positive and PI-positive) [172]. 
Cell cycle distribution was determined by flow cytometry using Vibrant DyeCycle Violet 
(DCV) DNA stain (V35003, Molecular Probes), which has been described previously [173]. 
Briefly, cells were detached with trypsin and resuspended in complete media at a cell 
concentration of 0.5-1 x 106 cells/mL. DCV DNA stain was added to a final concentration of 5-
10 μM and cells were incubated at 37°C for 40 min, protected from light. Unwashed and unfixed 
cells were analyzed using an LSR II flow cytometer or a FACSAria II cell sorter (Becton 
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Dickinson Biosciences). Cell cycle distributions were then computed using FCS Express 4 Flow 
Cytometry software. In overexpression experiments, cells overexpressing cyclin D1 or cyclin D2 
also expressed GFP, whereas cells overexpressing CDK4, CDK6, or CDKN1A also expressed 
RFP. Hence, corresponding gates were set to detect cell cycle distribution in the GFP-positive or 
RFP-positive cells, respectively. 
 
RNA isolation, reverse transcription, and real-time quantitative polymerase chain 
reaction (QPCR) 
Total RNA was extracted from the cells using Qiagen RNeasy Mini Kit (74106, Qiagen) 
with on-column DNase treatment (79254, Qiagen). Random-primed cDNA was prepared from 1 
μg of total RNA using the ProtoScript First Strand cDNA kit (E6300L, New England Biolabs, 
Ipswich, MA) and diluted 5-fold in water. One μl of diluted cDNA was used as template for 
QPCR using StepOnePlus Real-Time PCR System (Applied Biosystems, Grand Island, NY). 
Primers were designed using Primer3 (http://frodo.wi.mit.edu) and those that efficiently 
amplified [174] single products of the expected size were used for QPCR. Primer pairs for QPCR 
amplicons to detect mRNAs were as follows: cyclin D1 forward, 5’-
GGAAGTGTTGAAGGGAGGTG-3’; cyclin D1 reverse, 5’-
AACGGTAGCAGCGCAATAAG’; cyclin D2 forward, 5’-TCTTCGCTTCTGGTATCT-3’; 
cyclin D2 reverse, 5’-CTTGTCTGAGGAATGTTGT-3’; CDK4 forward, 5’-
GAGATTACTTTGCTGCCTTA-3’; CDK4 reverse, 5’-CCCTTAGTGTAGAGAAATGG-3’; 
CDK6 forward, 5’-TTCCGTTGATGTGCTTAG-3’; CDK6 reverse, 5’-
CTGAGAGTTGTTGGTGAT-3’; CDKN1A forward, 5’-ATCTTCTGCCTTAGTCTCA-3’; 
CDKN1A reverse, 5’-ACTCTTAGGAACCTCTCATT-3’. Primers for detecting pre-mRNAs 
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were as follows: cyclin D1 forward, 5’-CATCTACACCGACAACTC-3’; cyclin D1 reverse, 5’-
GGAGCAGATATGTCAGAG-3’; cyclin D2 forward, 5’-GGACATCCAACCCTACAT-3’; 
cyclin D2 reverse, 5’-TGGAGAGGAACAGAAATAAAG-3’; CDK4 forward, 5’-
CTTGCGGCCTGTGTCTATG-3’; CDK4 reverse, 5’-GGCACTGGTTCTCATTCCTG-3’; 
CDK6 forward, 5’-GAGAGTGCTGGTAACTCCTTCC-3’; CDK6 reverse, 5’-
AACCAAAGCCGATTCCAAG-3’; CDKN1A forward, 5’-CCGGCCAGGTAACATAGTG-3’; 
CDKN1A reverse, 5’-CATGGGTTCTGACGGACATC-3’. Primer pairs to detect distal 3’-UTR, 
proximal 3’-UTR, and exon1-exon2 junction were previously reported [175]. The QPCR was 
achieved using the following method: a denaturation and polymerase activation step at 94°C for 
1 min and then 40 cycle consisting of 94°C for 10 s, 57°C for 10 s, and 72°C for 20 s. Data were 
analyzed using the comparative threshold cycle (Ct) method [176] and multiple control genes, 
including GAPDH, TBP, RPL19, PYGO2, NUP88 and ADAM15, which are not regulated by 
androgen or AR. Following normalization to control gene cDNA levels, which is reflected in the 
ΔCt values, the relative quantification (RQ) of the fold change for each treatment compared to 
reference control was determined using the following equation: RQ = 2(–ΔCt) / 2(–ΔCt reference). The 
RQ mean and standard error of the mean (SEM) were plotted using log2 scale. 
 
Immunoblot analysis 
Immunoblots were performed to determine the relative expression of AR, cyclins, CDKs, 
CDKN1A, and phosphorylation of RB protein at various time points after treatment with 10 nM 
DHT or vehicle control. Cells were washed with PBS and harvested in 200μl of RIPA buffer (10 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 5% glycerol, 1 mM Na2EDTA, 1% Triton X-100, 0.1 % 
SDS, 0.1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
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mM NaF and protease inhibitors). Total cell lysates containing equal amounts of protein were 
subjected to 4-20% mini-TGX gel (456-1096, Bio-Rad, Hercules, CA) electrophoresis and then 
transferred to PVDF membranes. Non-specific binding was blocked by incubation of the 
membranes in TBST buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.1% Tween-20) 
containing 5% non-fat milk. Blots were incubated with rabbit antibodies raised against AR (06-
680, EMD Millipore, Billerica, MA), β-Actin (4970, Cell Signaling, Boston, MA), CCND1 
(2978, Cell Signaling), CCNE2 (4132, Cell Signaling), phospho-CDK2 (Thr160, 2561, Cell 
Signaling), CDK2 (2546, Cell Signaling), CDK4 (12790, Cell Signaling), CDKN1A (2947, Cell 
Signaling), GAPDH (2118, Cell Signaling) or mouse antibodies raised against CCND2 (ab3085, 
Abcam, Cambridge, MA), CCNA1 (MAB7046, R&D Systems, Minneapolis, MN), CDK4 
(2906, Cell Signaling), CDK6 (3136, Cell Signaling), phospho-RB (Ser780, 9307, Cell 
Signaling), phospho-RB (Ser807/811, 9308, Cell Signaling), or total RB (9309, Cell Signaling), 
followed by incubation with anti-rabbit or anti-mouse IgG, horseradish peroxidase (HRP)-linked 
antibody (7074 and #7076, Cell Signaling). The blots were visualized using Pierce ECL Western 
Blotting Substrates (32106/34080/34096, Thermo, Rockford, IL) and HyBlot CL 
Autoradiography Film (E3018, Denville Scientific, Metuchen, NJ). Films were scanned and 
Image J software was used to quantify protein expression relative to GAPDH, β-Actin, or total 
RB controls. 
 
Statistical analysis 
The significance differences among different groups were determined by one-way or two-
way analysis of variances (ANOVA), followed by Tukey’s honest significant difference test. To 
improve the validity of ANOVA, data that displayed non-normal or heteroscedastic variance 
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were transformed using Box-Cox power transformation [177]. A significance level of 0.05 was 
applied during data analysis, and different significance levels have been indicated using different 
lowercase letters. For time course analysis, significance differences between androgen treatment 
and vehicle control were determined at each time point using Student’s t-test and adjusted using 
the Bonferroni method. For cell cycle analysis, the proportions of G0/G1-phase cells in the 
different treatment groups were compared to indicate the significance differences. 
 
Results 
Inhibition of HPr-1AR cell proliferation in response to androgen 
HPr-1AR, which stably expresses wild-type AR (Fig. 2.1A), was derived from HPr-1 
human prostate epithelial cells by retroviral transduction [165,178]. Therefore, aside from the 
androgen sensitivity of HPr-1AR, these cell lines are isogenic. The proliferation of HPr-1AR and 
parental HPr-1 was compared in the presence of androgen. HPr-1AR proliferation was attenuated 
by 10 nM DHT, whereas HPr-1 was unaffected at 72 hours (Fig. 2.1B). Additional experiments 
with HPr-1AR showed significant decreases in cell proliferation at DHT doses ranging from 0.1-
10 nM (Fig. 2.1C). In time-course experiments, HPr-1AR cells proliferated in the presence of 
DHT, albeit at a decreased rate in comparison to vehicle-treated cells (Fig. 2.1D). To assess 
whether the decrease in cell proliferation rate was due to an increase in apoptosis, we examined 
cells stained with Alexa Fluor 488-annexin V, which binds phosphatidylserine, and PI nucleic 
acid dye following androgen treatment. DHT treatment did not significantly increase apoptosis in 
HPr-1AR cells (data not shown), which is consistent with the results of a previous study using 
mibolerone (a non-hydrolysable androgen) [165]. Also in HPr-1AR, the AR antagonist 2-
hydroxyflutamide (OHF) suppressed the antiproliferative effect of DHT (Fig. 2.1E) without 
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decreasing AR expression (Fig. 2.1F). Therefore, the attenuation of HPr-1AR cell proliferation in 
response to DHT is regulated by androgen signaling and is AR-dependent. 
In addition, cell cycle distribution was quantified by Vibrant DyeCycle Violet (DCV) 
staining of DNA and flow cytometry analysis, which have been described previously [173]. The 
proportion of cells in G0/G1 phase of the cell cycle was significantly increased 13% in cells 
treated with DHT for 24 hours compared to control, and the S-phase population was decreased 
13% leaving the G2/M population unchanged (Fig. 2.1G). Similar, although more modest, effects 
were observed at 48 hours. Together these data indicate that the inhibition of HPr-1AR 
proliferation by androgen is due to a prolonged G1 interval in the cell cycle. 
 
Regulation of cyclin expression by androgen in HPr-1AR 
Of the putative AR-regulated genes that we had previously identified in HPr-1AR [36], 
cyclin D1 (CCND1) was an intriguing candidate gene for the inhibition of HPr-1AR cell 
proliferation by androgen. However, cell cycle progression is thought to be regulated by the 
balance between the concentrations of activated cyclins and cyclin-dependent kinases (CDKs) 
[179], so we assessed the effect of androgen on the transcriptional regulation of additional cyclin 
and CDK genes, which were not interrogated in our previous study [36]. In HPr-1AR, the mRNA 
levels of several cyclin genes changed with DHT treatment (Fig. 2.2A). Specifically, cyclin D1 
and D2 mRNAs were strongly androgen-repressed, cyclin A1 was androgen-induced, and cyclins 
E2, A2, and B1-3 were modestly androgen-responsive. Importantly, these genes were 
unresponsive to androgen in the HPr-1 cells, which do not express AR (Fig. 2.2B). Additional 
experiments with HPr-1AR showed significant decreases in cyclin D1 and D2 mRNAs at DHT 
doses ranging from 0.1-10 nM (Fig. 2.2C), and OHF co-treatment suppressed the down-
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regulation of cyclin D1 and D2 mRNAs that occurred with DHT treatment (Fig. 2.2D). A time 
course analysis revealed that down-regulation of cyclin D1 and D2 mRNAs occurred by 8 hours 
and persisted for 48 hours or more (Fig. 2.11). Furthermore, the down-regulation of cyclin D1 
and D2 mRNAs led to decreased expression of each protein. Immunoblot analysis revealed that 
androgen treatment decreased cyclin D1 and D2 protein levels 75% or more at 24 hours and 70% 
or more at 48 hours (Fig. 2.2E-F). The levels of cyclin D3 protein increased 70% or more and 
cyclin E2 protein increased several fold with androgen treatment by 48 hours, whereas cyclin A1 
protein levels were unaffected by androgen treatment (Fig. 2.2E-F). 
 
Attenuation of CDK expression and cyclin D-CDK4/6 activity by androgen in HPr-
1AR 
Cyclin D proteins stimulate the G1/S-phase transition through association with and 
stabilization of CDK4/6, so we examined the expression of the CDKs and CDK inhibitors that 
may influence the activity of cyclin D-CDK4/6 complexes. CDK 4 and 6 were androgen-
repressed to a greater extent than CDK2 (Fig. 2.3A) in HPr-1AR. For the CDK inhibitors, 
CDKN1A mRNA was modestly DHT-induced, and CDKN1B mRNA was unresponsive to DHT 
in HPr-1AR. Moreover, CDK4, CDK6, and CDKN1A mRNAs were significantly regulated at 
DHT doses ranging from 0.1-10 nM (Fig. 2.3B), and OHF co-treatment suppressed the 
regulation of CDK4, CDK6, and CDKN1A mRNAs that occurred with DHT treatment (Fig. 
2.3C). A time course analysis revealed that the regulation of CDK4, CDK6, and CDKN1A 
mRNAs by androgen occurred by 16 hours and persisted for 48 hours or more (Fig. 2.11). 
Androgen treatment indeed decreased the expression of CDK4 and CDK6 proteins 55% or more 
at 24 hours (Fig. 2.3D-E) and 65% or more at 48 hours. CDK2 protein expression was unaffected 
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with androgen treatment, whereas CDK2 phosphorylation at threonine 160 (T160) was modestly 
decreased, albeit not significantly, at 24 and 48 hours. In addition, CDKN1A expression 
increased 280% with androgen treatment (Fig. 2.3D-E). Notably, androgen has been shown to 
modestly increase the expression of CDKN1A and CDKN1B proteins in HPr-1AR [165], which 
may also contribute to the G1-phase arrest in HPr-1AR. 
As phosphorylation of RB by cyclin D-CDK4/6 complexes initiates the G1/S-phase 
transition, we examined the relative activity of these complexes on RB phosphorylation. Our 
expectation was that decreased levels of cyclin D and CDK protein would lead to diminished RB 
phosphorylation in early G1 phase. In fact, RB phosphorylation at serine 780 (S780) and serine 
807/811 (S807/811), which are known substrates of cyclin D-CDK4/6 complexes, was reduced 
55% or more at 24 hours and 65% or more at 48 hours (Fig. 2.3D-E). To further assess the effect 
of AR-mediated down-regulation of cyclin D1/2 and CDK4/6 proteins on the activity of cyclin 
D-CDK4/6, we measured the relative proliferation of HPr-1AR cells treated with androgen and 
PD0332991, a CDK4/6-selective kinase inhibitor, or PD0332991 by itself. Remarkably, 
inhibiting the kinase activity of cyclin D-CDK4/6 with PD0332991 in combination with DHT 
diminished cell proliferation to the same extent as DHT by itself (Fig. 2.12), suggesting a 
common biochemical pathway for PD0332991 and DHT. Indeed, the decreased expression of 
cyclin D1/D2 and CDK4/6 and the reduced activity of the cyclin D-CDK4/6 complexes on RB 
phosphorylation are correlated with the reduction in HPr-1AR proliferation, since cyclin D and 
CDK protein levels were reduced by androgen and cell proliferation was potently inhibited by 
androgen. Taken together, these data indicate that down-regulation of cyclin D-CDK4/6 
complexes by AR is likely responsible for the G1-phase arrest of the cell cycle in HPr-1AR and 
attenuation of proliferation (Fig. 2.1). 
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AR-mediated destabilization of cyclin D1 mRNA in HPr-1AR 
We examined several possible mechanisms for down-regulation of cyclin D1 and D2 
transcripts by androgens, including direct transcriptional repression by AR at the cyclin D genes 
and destabilization and degradation of cyclin D transcripts. To assess whether androgen induced 
RNA destabilization and degradation of cyclin D and CDK mRNAs, HPr-1AR cells were treated 
with transcriptional inhibitor for 1 hour and then treated with 10 nM DHT or vehicle control (Fig 
4A). Following transcriptional inhibition by actinomycin D (ActD), a time course of androgen or 
control treatment was used to determine the half-life of transcripts for the PYGO2 control gene, 
which was unresponsive to androgen, and transcripts for the cyclin D genes and CDK genes. Of 
the cyclin D mRNAs, only cyclin D1 mRNA half-life was reduced (5 hours in DHT-treated 
samples compared to 10 hours in control samples) with androgen treatment (Fig 4B). Similar 
results were observed when transcription was inhibited using 5,6-
dichlororibofuranosylbenzimidazole (DRB) (Fig. 2.13), which inhibits transcription through a 
different mechanism from ActD. Thus, AR activation by DHT led to an increase in cyclin D1 
mRNA decay relative to vehicle control without changing the decay rates of cyclin D2, CDK4 
and CDK6 transcripts (Fig. 2.4B and Fig. 2.13). 
 
AR-mediated transcriptional regulation of cyclin D2, CDK4/6, and CDKN1A pre-
mRNAs in HPr-1AR 
In addition to the changes in mRNA levels of the cyclin D genes, we interrogated 
whether the down-regulation of cyclin D1 and D2 was due to transcriptional repression by AR. 
As precursor mRNA (pre-mRNA) is immature mRNA that has not undergone intron splicing, a 
change in pre-mRNA level is typically associated with transcriptional regulation rather than post-
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transcriptional modulation and therefore pre-mRNA serves as an indicator of ongoing 
transcription [180-183]. Pre-mRNA or nascent transcript levels can be used to approximate RNA 
polymerase transcription rates, as mRNA processing, including splicing, typically occurs within 
10 minutes of the completion of transcription [184]. Pre-mRNA levels were quantified in 
comparison to mature RNA levels using distinct QPCR amplicons (Fig. 2.5A-C). For cyclin D1 
transcripts, DHT treatment had little or no effect on pre-mRNA levels similar to vehicle control, 
whereas mature mRNAs containing sequences corresponding to E1-2 mRNA, proximal 3’-UTR, 
3’-UTR, and distal 3’-UTR were all androgen-repressed (Fig. 2.5B), indicating that full-length 
cyclin D1 mRNA was down-regulated in response to androgen in HPr-1AR. Alternative splicing 
of the cyclin D1 transcript has been described [185,186]. The cyclin D1b oncoprotein arises from 
alternative splicing of the CCND1 transcript, and it possesses enhanced oncogenic functions not 
shared by full-length cyclin D1 (cyclin D1a) [187-189]. The E1-2 mRNA amplicon was designed 
to detect both cyclin D1a and cyclin D1b mRNAs, whereas the 3’-UTR amplicons were designed 
to detect cyclin D1a mRNA. Full-length cyclin D1a mRNA was down-regulated by androgen 
signaling, though we cannot eliminate the possibility of cyclin D1b regulation. In striking 
contrast, cyclin D2 pre-mRNA was strongly DHT-repressed relative to vehicle control (Fig. 
2.5C), suggesting that the cyclin D2 gene was transcriptionally repressed by AR. Additional time 
course experiments, confirmed the transcriptional repression of nascent cyclin D2 transcripts 
upon DHT treatment, whereas cyclin D1 pre-mRNA levels were not significantly changed (Fig. 
2.14). CDK4 and CDK6 pre-mRNAs were also DHT-repressed relative to vehicle control (Fig. 
2.5D), which suggests that AR transcriptionally represses these CDK genes. In addition, 
CDKN1A pre-mRNA increased in response to DHT, indicating AR-mediated transcriptional 
activation (Fig. 2.5D). Taken together, the RNA stability data and the pre-mRNA data suggest 
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that multiple different mechanisms are responsible for the down-regulation of cyclin D and CDK 
transcripts and up-regulation of CDKN1A mRNA in HPr-1AR. We propose that cyclin D1 
mRNAs are down-regulated through a mechanism involving destabilization and degradation of 
the mature RNA without transcriptional repression and that cyclin D2, CDK4, and CDK6 
transcripts are regulated at the pre-mRNA level through AR-mediated transcriptional repression. 
The up-regulation of CDKN1A mRNA is also consistent with AR-mediated transcriptional 
activation, which has been reported previously in prostate cancer-derived cell lines [169,190]. 
 
Overexpression of cyclin D-CDK complex components rescues AR-mediated 
growth suppression of HPr-1AR 
To test whether changes in cyclin D expression affect the G1/S-phase transition of the cell 
cycle in HPr-1AR, we transiently overexpressed cyclin D1 or D2 and quantified the cell cycle 
distribution by DCV staining and flow cytometry analysis. Overexpression of cyclin D1 and D2 
proteins was confirmed by immunoblot analysis (Fig. 2.6A). For the vehicle-treated cells, 
overexpression of cyclin D1 or D2 decreased the proportion of cells in G0/G1 phase of the cell 
cycle by 5% and 3%, respectively, and increased the populations of cells in S phase and G2/M by 
5% and 3%, respectively (Fig. 2.6B). For the DHT-treated cells, overexpression of cyclin D1 or 
D2 decreased the proportion of cells in G0/G1 phase of the cell cycle by 6% and 4%, 
respectively, and increased the populations of cells in S phase and G2/M by 6% and 4%, 
respectively (Fig. 2.6B). Therefore, overexpression of cyclin D1 or D2 modestly suppressed the 
antiproliferative effect of DHT in HPr-1AR, based on the decrease in G0/G1-phase cells and the 
increase in S-phase cells (Fig. 2.6B). The AR-mediated inhibition of HPr-1AR proliferation that 
occurs with androgen treatment is consistent with a mechanism involving down-regulation of the 
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expression of endogenous cyclin D1 and D2, leading to a modest decrease in the activity of 
cyclin D-CDK4/6 complexes in the cell cycle. Nonetheless, the modest effect of cyclin D1/2 
overexpression on DHT-induced growth suppression of HPr-1AR suggests that additional AR-
regulated genes are involved in this process. 
To determine whether changes in CDK expression affect the G1/S-phase transition of the 
cell cycle in HPr-1AR, we stably overexpressed CDK4 or CDK6 and quantified the cell cycle 
distribution by DCV staining and flow cytometry analysis. Overexpression of CDK4 and CDK6 
proteins was demonstrated by immunoblot analysis (Fig. 2.6C). In comparison to vehicle-treated 
RFP control cells, overexpression of CDK4 or CDK6 decreased the proportion of cells in G0/G1 
phase of the cell cycle by 12% and 16%, respectively, increased the populations of cells in S 
phase and G2/M by 12% and 16%, respectively (Fig. 2.6D). In comparison to DHT-treated RFP 
control cells, overexpression of CDK4 or CDK6 decreased the proportion of cells in G0/G1 phase 
of the cell cycle by 19% and 25%, respectively, increased the populations of cells in S phase and 
G2/M by 19% and 25%, respectively (Fig. 2.6D). Furthermore, overexpression of either CDK4 or 
CDK6 completely suppressed the antiproliferative effect of DHT in HPr-1AR (Fig. 2.6E), which 
is consistent with the decrease in G0/G1 cells and the increase in S-phase and G2/M cells (Fig. 
2.6D). Therefore, we suggest the AR-mediated inhibition of HPr-1AR proliferation that occurs 
with androgen treatment is consistent with a mechanism involving down-regulation of the 
expression of endogenous CDK4 and CDK6, leading to a decrease in the activity of cyclin D-
CDK4/6 complexes, delaying the G1/S-phase transition of the cell cycle. 
In addition, we examined whether changes in CDKN1A expression affect the G1/S-phase 
transition of the cell cycle in HPr-1AR. To accomplish this, we stably overexpressed CDKN1A 
and assessed cell volume by quantifying forward and side light scatter using flow cytometry as 
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described previously [191]. Overexpression of CDKN1A protein was demonstrated by 
immunoblot analysis (Fig. 2.15). In comparison to parental HPr-1AR cells and RFP control cells, 
which have endogenous CDKN1A expression, overexpression of CDKN1A in HPr-1AR cells 
increased both forward and side light scatter values (Fig. 2.15), indicating that these cells have 
increased volume relative to the control cells. Our attempts to quantify cell cycle distribution 
using DCV stained cells were hampered by the increased DNA content of these enlarged cells 
with CDKN1A overexpression (Fig. 2.15). Notably, HPr-1AR cells with stable CDKN1A 
overexpression failed to divide in culture (data not shown). Taken together, these data suggest 
that increased CDKN1A expression induces cell cycle arrest in HPr-1AR. 
 
Inhibition of PC3-Lenti-AR cell proliferation in response to androgen 
For HPr-1AR, we have shown that AR regulates the expression of the cyclin D and CDK 
components of cyclin D-CDK4/6 complexes. As androgen activation of stably expressed AR has 
been shown to inhibit proliferation of PC-3 prostate cancer cells [154,169], we investigated the 
extent to which AR regulates cell cycle progression and cyclin D-CDK4/6 complexes in PC3-
Lenti-AR. The proliferation of PC3-Lenti-AR, which stably expresses wild-type AR (Fig. 2.7A), 
was inhibited by DHT treatment at 96 hours (Fig. 2.7B), which is consistent with the findings of 
Litvinov et al. [154]. PC3-Lenti-AR showed significant decreases in cell proliferation at DHT 
doses ranging from 1-10 nM (Fig. 2.7C). In time-course experiments, PC3-Lenti-AR cells 
proliferated in the presence of DHT, albeit at a decreased rate in comparison to vehicle-treated 
cells (Fig. 2.7D). OHF co-treatment also suppressed the antiproliferative effect of DHT (Fig. 
2.7E) without decreasing AR expression (Fig. 2.7F). In addition, the proportion of PC3-Lenti-
AR cells in G0/G1 phase of the cell cycle was increased 10% in cells treated with DHT for 24 
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hours compared to control, whereas the S-phase population was decreased 11% (Fig. 2.7G). By 
48 hours, the G0/G1 population was increased 34%, and the S-phase and G2/M populations were 
decreased 24% and 14%, respectively (Fig. 2.7G). 
 
Attenuation of CDK expression and cyclin D-CDK4/6 activity by androgen in PC3-
Lenti-AR 
In PC3-Lenti-AR, the expression of cyclin mRNAs and CDK2 and CDKN1B mRNAs 
were not significantly changed with DHT treatment (Fig. 2.8A-B). However, CDK 4 and 6 were 
androgen-repressed in PC3-Lenti-AR (Fig. 2.8B). In addition, CDKN1A mRNA was DHT-
induced, which is consistent with a previous report [154]. Moreover, CDK4, CDK6, and 
CDKN1A mRNAs were significantly regulated at DHT doses ranging from 0.1-10 nM (Fig. 
2.8C), and OHF co-treatment suppressed the regulation of CDK4, CDK6, and CDKN1A mRNAs 
that occurred with DHT treatment (Fig. 2.8D). A time course analysis revealed that the 
regulation of CDK4, CDK6, and CDKN1A mRNAs by androgen occurred by 8 hours and 
persisted for 24 hours or more (Fig. 2.16). CDK4 and CDK6 pre-mRNAs were also DHT-
repressed relative to vehicle control (Fig. 2.8E), implicating AR in the transcriptional repression 
of the CDK4 and CDK6 genes. In addition, CDKN1A pre-mRNA increased in response to DHT, 
implicating AR in the transcriptional activation of the CDKN1A gene (Fig. 2.8E), which is 
consistent with a previous report [169]. 
CDK4 and CDK6 protein expression was decreased 50% or more with androgen 
treatment at 24 hours and 65% or more at 48 hours. Phosphorylated CDK2 and total CDK2 
protein levels were also decreased 50% with DHT treatment at 48 hours (Fig. 2.8F-G). Litvinov 
et al. reported that androgen increases CDKN1A protein expression in PC3-Lenti-AR [154]. 
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Consistent with this report, we found that CDKN1A protein was indeed DHT-induced 
approximately 2 fold (Fig. 2.8F-G). Furthermore, RB phosphorylation at S780 and S807/811 was 
decreased 50% or more at 24 hours and 55% or more at 48 hours, and total RB protein levels 
were unaffected by androgen (Fig. 2.8F-G). Taken together, the proliferation inhibition (Fig. 
2.7B) and G1-phase arrest (Fig. 2.7G) programs that are activated by androgen action and the 
inhibition of RB phosphorylation suggest that the AR-mediated inhibition of PC3-Lenti-AR 
proliferation likely involves the regulation of cyclin D-CDK4/6 complexes, delaying the G1/S-
phase transition of the cell cycle. Hence, we propose that novel AR-mediated transcriptional 
repression of CDK4/6 expression together with elevated levels of CDK inhibitor CDKN1A are 
responsible for diminished RB phosphorylation and the AR-mediated inhibition of PC3-Lenti-
AR proliferation that occurs with androgen treatment, which is consistent with the findings of 
Litvinov et al. and Mirochnik et al. [154,169]. 
 
Overexpression of cyclin D-CDK complex components partially rescues AR-
mediated growth suppression of PC3-Lenti-AR 
To determine whether changes in CDK expression affect the G1/S-phase transition of the 
cell cycle in PC3-Lenti-AR, we stably overexpressed CDK4 or CDK6 and quantified the cell 
cycle distribution by DCV staining and flow cytometry analysis. Overexpression of CDK4 and 
CDK6 proteins was confirmed by immunoblot analysis (Fig. 2.9A). In comparison to vehicle-
treated RFP control cells, overexpression of CDK4 or CDK6 did not significantly change the 
proportion of PC3-Lenti-AR cells in the different phases of the cell cycle (Fig. 2.9B). In 
comparison to DHT-treated RFP control cells, overexpression of CDK4 or CDK6 decreased the 
proportion of cells in G0/G1 phase of the cell cycle by 3% and 11%, respectively, increased the 
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populations of cells in S phase and G2/M by 3% and 11%, respectively (Fig. 2.9B). Furthermore, 
CDK6 overexpression partially suppressed the antiproliferative effect of DHT in PC3-Lenti-AR 
(Fig. 2.9C), which is consistent with the decrease in G0/G1 cells and the increase in S-phase and 
G2/M cells (Fig. 2.9B). CDK4 overexpression showed a similar trend but did not significantly 
suppress the antiproliferative effect of DHT in PC3-Lenti-AR (Fig. 2.9C). Therefore, we suggest 
the AR-mediated inhibition of PC3-Lenti-AR proliferation that occurs with androgen treatment 
is consistent with a mechanism involving down-regulation of endogenous CDK4 and CDK6 
expression, leading to a decrease in the activity of cyclin D-CDK4/6 complexes in the cell cycle. 
We also examined whether changes in CDKN1A expression affect the G1/S-phase 
transition of the cell cycle in PC3-Lenti-AR. To do this, we stably overexpressed CDKN1A and 
assessed cell volume by quantifying forward and side light scatter using flow cytometry. 
Overexpression of CDKN1A protein was confirmed by immunoblot analysis (Fig. 2.17). In 
comparison to parental PC3-Lenti-AR cells and RFP control cells, which have endogenous 
CDKN1A expression, overexpression of CDKN1A in PC3-Lenti-AR cells increased both 
forward and side light scatter values (Fig. 2.17), indicating that these cells have increased 
volume relative to the control cell lines. Our attempts to quantify cell cycle distribution using 
DCV stained cells were again thwarted by the increased DNA content of the enlarged cells with 
CDKN1A overexpression (Fig. 2.17). Notably, PC3-Lenti-AR cells with stable CDKN1A 
overexpression failed to divide in culture (data not shown). These finding indicate that increased 
CDKN1A expression induces cell cycle arrest in PC3-Lenti-AR, which is consistent with a 
previous report by Mirochnik et al. [169]. 
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Discussion 
The antiproliferative actions of androgens in non-malignant prostate epithelial cells have 
been demonstrated in vivo and in several cellular contexts, although the mechanism whereby AR 
restrains cell proliferation of prostate epithelial cells is not understood. DHT inhibited HPr-1AR 
and PC3-Lenti-AR cell proliferation, and cell cycle analysis revealed a prolonged G1 interval in 
response to androgen (Figs. 1 and 7). We found multiple genes involved in cell cycle progression 
and proliferation to be regulated by AR in HPr-1AR and PC3-Lenti-AR (Figs. 2, 3, and 8). AR-
dependent mechanisms decreased the expression and activity of cyclin D1/2-CDK4/6 complexes 
on RB phosphorylation. In HPr-1AR, cyclin D1 mRNA was destabilized and exhibited a shorter 
half-life following androgen treatment, whereas cyclin D2, CDK4, and CDK6 mRNAs were 
transcriptionally repressed (Figs. 4 and 5). Similar AR-mediated down-regulation of CDK4 and 
CDK6 nascent transcripts occurred in PC3-Lenti-AR (Fig. 2.8). In addition, CDKN1A pre-
mRNA was androgen-induced in both prostate cell lines (Figs. 3 and 8). Furthermore, 
overexpression of CDK4 or CDK6 suppressed DHT-inhibited cell cycle progression and 
proliferation in HPr-1AR and PC3-Lenti-AR (Figs. 6 and 9), whereas CDKN1A overexpression 
induced cell cycle arrest (S5 and S7 Figs.). We therefore propose that the mechanism responsible 
for AR-mediated inhibition of HPr-1AR and PC3-Lenti-AR cell proliferation involves down-
regulation of cyclin D-CDK4/6 complexes through transcriptional repression of the CDK4 and 
CDK6 genes and transcriptional activation of the CDKN1A gene (Fig. 2.10). We also propose 
that AR-mediated decreases in cyclin D expression via cyclin D1 mRNA decay and cyclin D2 
transcriptional repression contribute to HPr-1AR growth suppression (Fig. 2.10). 
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AR-mediated regulation of prostate epithelial cell proliferation 
Previous studies comparing PC3-Lenti-AR to PC-3 and HPr-1AR to HPr-1 have shown 
that AR expression is necessary for androgen-induced growth suppression of these cell lines 
[154,165]. In the present study, we have provided substantial evidence for the mechanism of AR-
mediated growth suppression using these prostate cell lines. Both PC3-Lenti-AR and HPr-1AR 
were derived from androgen-insensitive prostate epithelial cell lines, but they are distinguished 
by their ability to form tumors. PC-3 cells are castration-resistant prostate adenocarcinoma cells 
that have high metastatic potential, whereas HPr-1 cells are immortalized, benign prostate 
epithelial cells [154,165,166,178,192]. In addition, stable expression of AR in PC-3 prostate 
cancer cells profoundly suppressed cell proliferation and tumor growth in intact-male mouse 
xenografts [154]. 
Many prostate cancer cells derived from tumor parenchyma express AR, and they are 
somewhat dependent on AR activation for growth and proliferation [123,126-130,144]. 
Androgen action and cell cycle progression has been examined in AR-immunoreactive cancer 
cells. Androgen ablation in vivo initially induces apoptosis in a subset of prostate cancer cells, 
leading to tumor regression, and induces G1-phase arrest in those that survive, which is 
evidenced by subsequent tumor regrowth [127,131,145-147]. However, prostate cancer cells 
derived from castrated patients, such as LNCaP, LAPC-4, MDA-PC-2B, VCAP, and so on, are 
dependent upon androgens for growth and proliferation, and they are thought to have 
mechanisms of castration resistance (including AR mutation, amplification, and constitutively 
active splice variants) as a strategy to survive in the presence of castrate levels of androgen [132-
135]. Studies using castration-resistant LNCaP cells have reported that androgen stimulates the 
proliferation of prostate cancer cells by enhancing the expression of G1/S regulatory proteins, 
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whereas androgen withdrawal causes G1-phase arrest [127,144,193-196]. Indeed, the 
proliferative actions of androgen-activated AR are well known in malignant epithelial cells of 
prostate origin. However, one should not conclude that androgen is a positive proliferative signal 
in all prostate epithelial cells. For example, E006AA and PC-3 prostate cancer cells display a 
complete absence of AR growth-regulatory function due to loss of AR-dependent growth 
suppression [154,166-168,197]. Therefore, prostate cancer cell lines like LNCaP (AR-positive) 
and PC-3 (AR-negative) may have evolved/adapted gene expression programs, through AR-
mutation or p53-mutation, to escape the growth suppressive actions of androgens [154,198-200]. 
AR signaling has been suggested to function as a negative regulator of epithelial 
proliferation in the prostate gland. Such a role for AR is supported by compelling experiments in 
AR knockout mice that have demonstrated that AR expression in intermediate cells is necessary 
for growth suppression and differentiation of these cells into luminal epithelial cells [119,120]. 
Ling et al. reported that immortalized non-tumorigenic HPr-1AR cells undergo growth 
suppression and cytodifferentiation in response to mibolerone (a non-hydrolysable androgen 
analog) [165], which is consistent with our results that the endogenous androgen DHT is a potent 
inhibitor of their proliferation (Fig. 2.1). Importantly, normal secretory luminal epithelial cells in 
the prostate, which express AR, are well-differentiated and quiescent, as androgen does not 
stimulate their proliferation [122,159]. Thus, AR signaling restrains proliferation of normal 
prostate epithelial cells. 
 
AR-mediated regulation of cell cycle progression 
Here, we have provided evidence for AR-mediated regulation of cell cycle progression at 
the G1/S-phase transition as a mechanism for growth suppression of HPr-1AR and PC3-Lenti-
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AR (Figs. 1-3 and 7-8). In the cell cycle, G1-phase progression is regulated by the expression, 
formation, and activation of cyclin-CDK complexes. Cyclin D-CDK4/6 complexes are important 
for the G1/S-phase transition because they increase RB-phosphorylation, activation of E2F 
transcription factors and expression of S phase promoting genes [76,164]. In addition, we 
discovered that DHT-induced inhibition of HPr-1AR and PC3-Lenti-AR proliferation (Figs. 1 
and 7) is associated with the reduced expression and activity of cyclin D1/2-CDK4/6 complexes 
on RB phosphorylation (Figs. 3 and 8). Furthermore, stable overexpression of CDK4/6 
completely suppresses the DHT-induced G1-phase delay and restrained proliferation of HPr-1AR 
cells (Fig. 2.6) and partially suppressed the DHT-induced G1-phase delay and inhibited 
proliferation of PC3-Lenti-AR cells (Fig. 2.9). Taken together, these results suggest that AR-
mediated down-regulation of cyclin D-CDK4/6 complexes is a crucial mechanism through which 
androgen signaling inhibits cell cycle progression and exerts growth suppression in non-
tumorigenic HPr-1AR and invasive PC3-Lenti-AR cells. The delay in cell cycle progression at 
the G1/S-phase transition and growth suppression in these cells likely involve multiple AR-
mediated mechanisms that serve to regulate the expression and activity of cyclin-CDK 
complexes. 
Of the G1/S-phase cyclins, the expression of cyclin D1 and cyclin D2 was substantially 
decreased and cyclin D3 protein was modestly increased in androgen-treated HPr-1AR (Figs. 2, 
4, and 5), whereas their expression was unaffected by androgen in PC3-Lenti-AR (Fig. 2.8). In 
HPr-1AR, we also found that cyclin D1/2 overexpression stimulated G1/S-phase progression and 
modestly suppressed the DHT-induced G1-phase delay in these epithelial cells (Fig. 2.6B), which 
led us to conclude that AR-mediated regulation of cyclin D1/2 expression modulates G1/S-phase 
progression and growth suppression. Additional support for this conclusion comes from the 
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finding that cyclin D1 overexpression in LNCaP prostate cancer cells increased the fraction of S-
phase cells and decreased growth factor requirements for their proliferation [194]. Cyclin D3 has 
been shown to positively regulate terminal cytodifferentiation in multiple tissues, including 
skeletal muscle and liver [201-204]. Therefore, the up-regulation of cyclin D3 may also 
contribute to the androgen-induced differentiation and growth suppression that was previously 
reported for HPr-1AR [165]. Several additional G1/S-phase cyclins that partner with CDK2 were 
androgen responsive in HPr-1AR cells. Cyclin E2 expression was DHT-induced, whereas cyclin 
A2 and B1-3 mRNAs were modestly DHT-repressed (Fig. 2.2). The altered expression of these 
cyclins in HPr-1AR might affect CDK2 stability and activity. However, the levels of 
phosphorylated CDK2 and total CDK2 expression remained unchanged with androgen treatment 
(Fig. 2.3), suggesting that CDK2 stability and activity were unaffected by the altered expression 
of cyclins A, B, and E in DHT-treated HPr-1AR cells. While we cannot eliminate the possibility 
that CDKN1A up-regulation suppresses CDK2 activity in HPr-1AR, our results demonstrate the 
importance of cyclin D-CDK4/6 complexes and the G1/S-phase transition in AR-mediated 
growth suppression. 
In human non-transformed prostate epithelial cells, the expression of p53 and CDKN1A 
has been shown to increase with androgen treatment [205]. Consistent with previous reports 
[154,165], we observed CDKN1A up-regulation in DHT-treated HPr-1AR and PC3-Lenti-AR 
cells (Figs. 3 and 8). These findings support the idea that G1-phase progression is further 
regulated by cellular signals that activate p53 and increase the expression of CDK inhibitors, 
including CDKN1A. At low concentrations (i.e., basal expression), CDKN1A has been shown to 
promote assembly of active cyclin D-CDK complexes and G1/S-phase transition, whereas at 
higher concentrations (i.e., induced expression), CDKN1A has been shown to inhibit the activity 
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of cyclin E-CDK2 and cyclin D-CDK4/6 complexes and decrease cell proliferation 
[161,163,206]. Based on these findings and our results that CDKN1A overexpression induces 
G1-phase arrest in HPr-1AR and PC3-Lenti-AR cells (S5 and S7 Figs.), which are consistent 
with results from Mirochnik et al. [169], we conclude that AR-mediated inhibition of G1/S-phase 
progression and cell proliferation also involves the CDK inhibitory activity of CDKN1A.  
An intriguing difference between HPr-1AR and PC3-Lenti-AR is that the DHT-induced 
G1 arrest of HPr-1AR cells appears to be “transient” in comparison to the G1 arrest of PC3-Lenti-
AR cells (compare Fig. 2.1G to Fig. 2.7G). The PC3-Lenti-AR data suggests that the DHT-
treated PC3-Lenti-AR cells continue through the cell cycle until they arrest in G1 phase of the 
next cycle, which may be due to an absence of p53 in these cells [207,208]. Based on the HPr-
1AR cell cycle data, one should not conclude that DHT-induced growth suppression of HPr-1AR 
is transient. The substantial decrease in phosphorylated RB protein at 24 and 48 hours (Fig. 2.3) 
together with diminished proliferation of DHT-treated HPr-1AR cell at 2-4 days (Fig. 2.1) 
provide evidence that AR-mediated growth suppression of HPr-1AR persists for 48 hours or 
more. 
 
AR-mediated transcriptional regulation of cyclin D1/2, CDK4/6, and CDKN1A 
In a previous study using HPr-1AR, we identified cyclin D1 as an AR-occupied ARG, 
based on the presence of an AR-occupied binding sequence within 50 kb of its transcription start 
site (GGAACGtccAGTGCC is 4.8 kb upstream of the transcription start site in intron 3) [36]. 
This same sequence is also occupied by the closely related glucocorticoid receptor (GR) in A549 
cells treated with GR agonist, dexamethasone [209]. GR binds in vitro with similar affinity as 
AR to consensus sequences in the elementary half-sites GGTACAnnnTGTTCT [14]. However, 
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the finding that androgen treatment decreased the half-life of cyclin D1 mRNA (Fig. 2.4) without 
decreasing cyclin D1 pre-mRNA levels (Fig. 2.5) indicates that post-transcriptional control of 
mRNA decay [180] is a central mechanism through which AR signaling regulates cyclin D1 
expression in HPr-1AR. Cyclin D1 mRNA destabilization and decay could occur by dissociation 
of mRNA stabilizing factors from cyclin D1 transcripts or by association of an androgen-induced 
miRNA. The miR-34a miRNA has been shown to target the 3’-untranslated mRNA region of 
cyclin D1 and decrease its expression [210]. Further, the introduction of miR-34a precursor into 
PC-3 cells resulted in cell growth inhibition and G1-phase arrest [211]. Additional experiments 
designed to identify sequences in the cyclin D1 mRNA that are responsible for transcript 
destabilization and decay are needed to define the exact role of AR in this mechanism. 
Although the stability of cyclin D2 mRNA was unaffected by DHT treatment, cyclin D2 
pre-mRNA was androgen-repressed, implicating AR in the transcriptional repression of cyclin 
D2 (Fig. 2.5). Although AR occupancy at the cyclin D2 locus was not interrogated in our 
previous study [36], GR occupancy data from the ENCODE Consortium identify a GR-occupied 
region 47 kb upstream of the cyclin D2 transcription start site in dexamethasone-treated A549 
cells [209]. Indeed, the AR-mediated mechanisms responsible for cyclin D1 and D2 down-
regulation by androgen in HPr-1AR differ from the post-transcriptional mechanism that 
reportedly increases cyclin D1/2 expression in LNCaP prostate cancer cells [212]. 
We also found that CDK4 and CDK6 nascent transcripts were androgen-repressed in 
HPr-1AR and PC3-Lenti-AR (Figs. 5 and 8), which is consistent with AR-mediated 
transcriptional repression of these CDK genes. In LNCaP cells, which proliferate with androgen, 
CDK4 mRNA was previously shown to be androgen-induced [144]. Although we have not 
interrogated AR occupancy at CDK4 and CDK6 in HPr-1AR and PC3-Lenti-AR, an AR-
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occupied region was identified 530 bp upstream of the transcription start site of CDK4 in LNCaP 
cells [43]. The ENCODE Consortium data for dexamethasone-treated A549 cells also identify a 
GR-occupied region at the transcription start site of the CDK4 gene and 12 or more GR-occupied 
regions in several introns of the CDK6 gene [209]. 
CDKN1A expression is indeed androgen-stimulated in HPr-1AR and PC3-Lenti-AR 
(Figs. 3 and 8), which is consistent with previous reports [154,165,212,213]. Transcriptional 
activation of the CDKN1A gene may involve direct binding of ligand-bound AR at a functional 
AR binding sequence that was previously identified 200 bp upstream of the transcription start 
site of transcript variant 1 [190]. In addition to this AR binding sequence being a GR-occupied 
region in dexamethasone-treated A549 cells, GR occupancy data from the ENCODE Consortium 
identify 5 additional GR-occupied regions at the CDKN1A locus (3 regions are located 9-33 kb 
upstream of the transcription start site and 2 regions are in intron 1) [209]. 
 
Conclusions 
Multiple mechanisms are responsible for the AR-mediated growth suppression of HPr-
1AR and PC3-Lenti-AR. In HPr-1AR, AR-mediated inhibition of proliferation involves down-
regulation of cyclin D-CDK complexes through transcriptional repression of cyclin D2, CDK4, 
and CDK6 mRNAs, destabilization of cyclin D1 mRNA, and transcriptional activation of 
CDKN1A mRNA. In PC3-Lenti-AR, AR-mediated growth suppression occurs through a similar 
mechanism, albeit without down-regulation of cyclin D1/2 expression. Our findings have 
revealed a central role for several ARGs in HPr-1AR and PC3-Lenti-AR whereby AR-mediated 
changes in the expression and activity of cyclin D-CDK4/6 complexes suppress cell cycle 
progression and proliferation of these prostate epithelial cells. Therefore, future studies should 
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extend our cell culture analysis to assess the AR-mediated regulation of these ARGs and their 
relative contribution to epithelial cell proliferation in developing and adult prostate tissue, and 
during neoplastic disease progression in the prostate. It will be important to determine how AR 
decreases cyclin D1 mRNA stability and represses transcription of the cyclin D2, CDK4, and 
CDK6 genes and whether these mechanisms can be exploited for therapeutic intervention in 
prostate neoplasia and malignancy. Future studies designed to address these unknowns will 
provide additional insight into regulatory mechanisms operating within hormone-responsive 
gene networks. 
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Figures 
 
Fig. 2.1 Inhibition of HPr-1AR cell proliferation in response to androgen.  
(A) HPr-1AR cells and parental HPr-1 cells were treated with 10 nM DHT or vehicle control for 24 
hours, and immunoblots show robust AR protein expression in HPr-1AR lysates compared to HPr-1 
lysates. (B) HPr-1 and HPr-1AR cells were treated with 10 nM of DHT or vehicle control, and the relative 
number of viable cells was determined after 72 hours of treatment by quantification of ATP in 
metabolically active cells. Cell number increased for all treatments, however, 52% fewer HPr-1AR cells 
were present following treatment with DHT compared to vehicle control. HPr-1 cell number was 
unaffected by DHT. Data represent the mean ± SEM, n=4. (C) HPr-1AR cells were treated with several 
DHT doses (10-12, 10-11, 10-10, 10-9, 10-8 M) or vehicle control for 72 hours, and significant decreases in 
cell proliferation occurred at doses ranging from 0.1-10 nM DHT, n=4. (D) In time course experiments, 
HPr-1AR cells proliferated in the presence of 10 nM DHT, albeit at a decreased rate. In comparison to 
control-treated HPr-1AR cells, 31%, 48%, and 63% fewer HPr-1AR cells were present following 
treatment with DHT for 2, 3, and 4 days (48, 72, and 96 hours), respectively. Data represent the mean ± 
SEM, n=6. (E) In HPr-1AR, 2-hydroxyflutamide (OHF, 10 μM) suppressed the antiproliferative effect of 
1 nM DHT at 72 hours, n=4. (F) HPr-1AR cells were treated with various combinations of 1 nM DHT 
and 10 μM OHF or vehicle control for 24 hours, and immunoblots show robust AR protein expression in 
HPr-1AR lysates. (G) HPr-1AR cells were treated with 10 nM DHT or vehicle control, and the fraction of 
cells in different phases of the cell cycle was measured by DCV staining followed by FACS analysis at 24 
and 48 hours (h). DHT treatment significantly increased the G0/G1 population by 13% at 24 hours and 5% 
at 48 hours compared to the control and decreased the S-phase and G2/M populations by 13% and 5%, 
respectively. Data represent the mean, n=3. * P < 0.05. Different significance levels have been indicated 
using different lowercase letters. 
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Fig. 2.2 Regulation of cyclin expression by androgen in HPr-1AR. 
(A) After treatment with 10 nM DHT or vehicle control for 24 hours, total RNA was isolated from HPr-
1AR and HPr-1 cells, cDNA was synthesized by reverse transcription and relative levels of cyclin 
mRNAs were quantified by QPCR analysis. Among the cyclins, cyclin D1 and D2 mRNAs were 
androgen-repressed 7 fold and 14 fold compared to vehicle control, respectively, and cyclin A2, B1, B2, 
and B3 were also androgen-repressed. In addition, cyclin E2 and A1 mRNAs were androgen-induced. 
Data represent the mean ± SEM, n=3. (B) However, cyclin mRNAs were unchanged in HPr-1 cells 
treated with 10 nM DHT, n=3. (C) HPr-1AR cells were treated with several DHT doses (10-11, 10-10, 10-9, 
10-8 M) or vehicle control for 24 hours, and significant decreases in cyclin D1 and D2 mRNAs occurred 
at DHT doses ranging from 0.1-10 nM, n=3. (D) AR antagonist 2-hydroxyflutamide (OHF, 10 μM) 
suppressed the down-regulation of cyclin D mRNAs by 1 nM DHT treatment at 24 hours, n=3. (E) HPr-
1AR cells were treated with 10 nM DHT or vehicle control for 24-48 hours (h), and immunoblot analysis 
of cell lysates reveals that cyclin D1 and D2 protein expression decreased substantially with DHT 
treatment compared to vehicle. (F) DHT treatment significantly decreased cyclin D1 and D2 protein 
levels 75% or more at 24 hours and 70% or more at 48 hours. In contrast, the expression of cyclin D3 and 
cyclin E2 increased 70% and 170% with DHT treatment at 24 hours, respectively, and they increased 
85% and 420% at 48 hours, respectively. Relative Cyclin/GAPDH and AR/GAPDH protein ratios are 
shown using the mean ± SEM, n=4. * P < 0.05. 
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Fig. 2.3 Attenuation of CDK expression and cyclin D-CDK4/6 activity by androgen in HPr-1AR.  
(A) HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24 hours, and CDK2, CDK4 and 
CDK6 mRNAs and CDKN1A and CDKN1B mRNAs were quantified using QPCR. CDK4 and CDK6 
mRNAs were androgen-repressed 2-3 fold. CDKN1A mRNA was DHT-induced 2-fold whereas 
CDKN1B mRNA was unresponsive to DHT. Data represent the mean ± SEM, n=3. (B) HPr-1AR cells 
were treated with several DHT doses (10-11, 10-10, 10-9, 10-8 M) or vehicle control for 24 hours, and 
significant decreases in CDK4 and CDK6 mRNAs occurred at DHT doses ranging from 0.1-10 nM, n=3. 
These DHT doses also increased CDKN1A mRNA. (C) AR antagonist 2-hydroxyflutamide (OHF, 10 
μM) suppressed the down-regulation of CDK mRNAs and the up-regulation of CDKN1A mRNA by 1 
nM DHT treatment at 24 hours, n=3. (D) HPr-1AR cells were treated with 10 nM DHT or vehicle control 
for 24-48 hours (h). Immunoblot analysis of cell lysates reveals that CDK4 and CDK6 protein expression 
decreased and CDKN1A expression increased with DHT treatment compared to vehicle. CDK2 
phosphorylation at threonine 160 (T160) decreased nearly 50% with androgen treatment at 24 and 48 
hours, albeit not significantly, and total CDK2 protein expression remained unchanged. Relative to total 
RB expression, the levels of various phosphorylated forms of RB (S780 and S807/811) decreased over 
time with androgen treatment. (E) DHT treatment significantly decreased CDK4 and CDK6 protein levels 
55% or more at 24 hours and 65% or more at 48 hours. The phosphorylated forms of RB declined 55% or 
more at 24 hours and 65% or more at 48 hours. Relative CDK/GAPDH and p-RB/total RB protein ratios 
are shown using the mean ± SEM, n=4. * P < 0.05. 
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Fig. 2.4 AR-mediated destabilization of cyclin D1 mRNA in HPr-1AR.  
(A) Experimental design scheme depicts transcriptional inhibition by actinomycin D (ActD), DHT 
treatment, and mRNA isolation. Cells were treated with transcription inhibitor, ActD, for 1 hour prior to 
treatment with 10 nM DHT or vehicle control, and total RNA was harvested at the indicated time points 
for quantification by QPCR. (B) Transcription of the PYGO2 control gene was unchanged by androgen, 
and the half-life of its mRNAs was unaffected. The half-lives of cyclin D2, CDK4, and CDK6 mRNAs 
were unchanged by DHT treatment compared to vehicle control, whereas the cyclin D1 mRNA half-life 
was 5 hours (h) in DHT-treated samples compared to 10 hours in control samples. Data represent the 
mean ± SEM, n=3. 
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Fig. 2.5 AR-mediated transcriptional regulation of cyclin D2, CDK4/6, and CDKN1A pre-mRNAs 
in HPr-1AR.  
(A) Depiction of QPCR amplicons that were designed to detect various regions of cyclin D1 pre-mRNA 
and mRNA. The 5’ and 3’ untranslated regions (UTRs) are depicted at each end of the cyclin pre-mRNA, 
vertical rectangles represent exons and horizontal lines represent introns. (B) In comparison to control 
samples, DHT treatment for 24 hours decreased cyclin D1 mRNAs by 6 fold or more without significant 
changes in cyclin D1 pre-mRNAs, indicating that AR-mediated regulation was restricted to the spliced 
mRNA transcripts. (C) In comparison to control samples, DHT treatment for 24 hours decreased cyclin 
D2 mRNA and pre-mRNA 8 fold or more, suggesting AR-mediated regulation through transcriptional 
repression. (D) DHT treatment for 24 hours also decreased CDK4 and CDK6 mRNAs and pre-mRNAs 2 
fold or more compared to control treatment, suggesting AR-mediated regulation through transcriptional 
repression. In addition, CDKN1A mRNA and pre-mRNA increased in response to DHT, implicating AR-
mediated regulation via transcriptional activation of CDKN1A. Data represent the mean ± SEM, n=3. * P 
< 0.05. 
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Fig. 2.6. Overexpression of cyclin D-CDK complex components rescues AR-mediated growth 
suppression of HPr-1AR.  
(A) Transient overexpression of cyclin D1 and cyclin D2 was validated by immunoblot analysis. (B) 
Transient overexpression of either cyclin D1 or cyclin D2 decreased the proportion of HPr-1AR cells in 
G0/G1 phase of the cell cycle and increased the proportion of cells in S phase. However, the increases in 
cell cycle progression due to cyclin D1 and cyclin D2 overexpression remained completely sensitive to 
androgen, such that DHT treatment increased the G0/G1 populations by the same amount (6-7%) before  
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Fig. 2.6 (cont.) 
and after transient overexpression of cyclin D1 or D2. The expression vectors used in these experiments 
also express green fluorescent protein, which allowed for gating and analysis of transfected cells among a 
background of untransfected cells. (C) Stable overexpression of CDK4 and CDK6 was validated by 
immunoblot analysis. (D) Stable overexpression of either CDK4 or CDK6 decreased the proportion of 
HPr-1AR cells in G0/G1 phase of the cell cycle and increased the proportion of cells in S phase. 
Moreover, the cell cycle progression after CDK4 and CDK6 overexpression became completely resistant 
to androgen, such that the proportions of cells in G0/G1, S, and G2/M phases of the cell cycle were 
unaffected by DHT treatment. The integrated proviral vectors used in these experiments also express red 
fluorescent protein, which allowed for sorting, gating and analysis of transduced cells among a 
background of uninfected cells. (E) Stable overexpression of either CDK4 or CDK6 increased the 
proliferation of HPr-1AR cells. In addition, the increases in proliferation due to CDK4 and CDK6 
overexpression became completely resistant to DHT treatment. * P < 0.05. 
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Fig. 2.7 Inhibition of PC3-Lenti-AR cell proliferation in response to androgen.  
(A) PC3-Lenti-AR (PC3-AR) cells and parental PC-3 (PC3) cells were treated with 10 nM DHT or 
vehicle control for 24 hours, and immunoblots show robust AR protein expression in PC3-Lenti-AR 
lysates compared to PC-3 lysates. (B) PC3-Lenti-AR and PC-3 cells were treated with 10 nM of DHT or 
vehicle control, and the relative number of viable cells was determined after 96 hours of treatment by 
quantification of ATP in metabolically active cells. Cell number increased for all treatments, however, 
42% fewer PC3-Lenti-AR cells were present following treatment with DHT compared to vehicle control. 
PC-3 cell number was unaffected by DHT. Data represent the mean ± SEM, n=6. (C) PC3-Lenti-AR cells 
were treated with several DHT doses (10-12, 10-11, 10-10, 10-9, 10-8 M) or vehicle control for 96 hours, and 
significant decreases in cell proliferation occurred at doses ranging from 1-10 nM DHT, n=6. (D) In time 
course experiments, PC3-Lenti-AR cells proliferated in the presence of DHT, albeit at a decreased rate. In 
comparison to control-treated PC3-Lenti-AR cells, 24%, 36%, and 63% fewer PC3-Lenti-AR cells were 
present following treatment with DHT for 3, 4, and 6 days (72, 96, and 144 hours), respectively. Data 
represent the mean ± SEM, n=8. (E) In PC3-Lenti-AR, 2-hydroxyflutamide (OHF, 10 μM) suppressed the 
antiproliferative effect of 1 nM DHT at 96 hours, n=6. (F) PC3-Lenti-AR cells were treated with various 
combinations of 1 nM DHT and 10 μM OHF or vehicle control for 24 hours, and immunoblots show 
robust AR protein expression in PC3-Lenti-AR lysates. (G) PC3-Lenti-AR cells were treated with 10 nM 
DHT or vehicle control, and the fraction of cells in different phases of the cell cycle was measured by 
DCV staining followed by FACS analysis at 24 and 48 hours (h). DHT treatment significantly increased 
the G0/G1 population by 10% at 24 hours compared to the control and decreased the S-phase population 
by 11%, increasing the G2/M population by 2%. At 48 hours, DHT treatment robustly increased the G0/G1 
population by 34% compared to the control and decreased the S-phase and G2/M populations by 24% and 
10%, respectively. Data represent the mean, n=3. * P < 0.05. 
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Fig. 2.8 Attenuation of CDK expression and cyclin D-CDK4/6 activity by androgen in PC3-Lenti-
AR.  
PC3-Lenti-AR cells were treated with 10 nM DHT or vehicle control for 24 hours, and (A) cyclin mRNA 
levels and (B) CDK and CDK inhibitor mRNA levels were determined using QPCR. The cyclin, CDK2, 
and CDKN1B mRNAs were unaffected by androgen treatment, whereas CDK4 and CDK6 mRNAs were 
androgen-repressed 1.8 fold or more. CDKN1A mRNA was DHT-induced 2.3 fold or more at 24 hours. 
Data represent the mean ± SEM, n=3. (C) PC3-Lenti-AR cells were treated with several DHT doses (10-
10, 10-9, 10-8 M) or vehicle control for 24 hours, and significant decreases in CDK4 and CDK6 mRNAs 
occurred at DHT doses ranging from 0.1-10 nM, n=3. These DHT doses also increased CDKN1A mRNA. 
(D) AR antagonist 2-hydroxyflutamide (OHF, 10 μM) suppressed the down-regulation of CDK mRNAs  
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Fig. 2.8 (cont.) 
and the up-regulation of CDKN1A mRNA by 1 nM DHT treatment at 24 hours, n=3. (E) In comparison 
to control samples, DHT treatment for 24 hours significantly decreased CDK4 and CDK6 mRNAs and 
pre-mRNAs 1.5 fold or more and increased CDKN1A mRNA and pre-mRNA 2 fold or more, suggesting 
AR-mediated regulation of transcription at these genes, n=3. (F) PC3-Lenti-AR cells were treated with 10 
nM DHT or vehicle control for 24-48 hours (h), and immunoblot analysis of cell lysates reveals that the 
relative levels of the CDK proteins and various phosphorylated forms of RB (S780 and S807/811) 
decreased and CDKN1A expression increased over time with androgen treatment compared to vehicle. 
(G) CDK4 and CDK6 proteins were reduced 50% or more at 24 hours and 65% or more at 48 hours, and 
phosphorylated CDK2 as well as total CDK2 protein decreased 50% with androgen treatment at 48 hours. 
In addition, the phosphorylated forms of RB declined 50% or more at 24 hours and 55% or more at 48 
hours. Relative Cyclin D/GAPDH, CDK/GAPDH and AR/GAPDH and p-RB/total RB protein ratios are 
shown using the mean ± SEM, n=4. * P < 0.05. 
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Fig. 2.9 Overexpression of cyclin D-CDK complex components partially rescues AR-mediated 
growth suppression of PC3-Lenti-AR. 
(A) Stable overexpression of CDK4 and CDK6 was validated by immunoblot analysis. (B) In the absence 
of DHT, stable overexpression of CDK4 and CDK6 did not significantly decrease the proportion of PC3-
Lenti-AR cells in G0/G1 phase of the cell cycle. However, in the presence of 10 nM DHT, overexpression 
of CDK4 and CDK6 partially but significantly attenuates the DHT-induced cell cycle arrest by 2% and 
8%, respectively. The integrated viral vectors used in these experiments also express red fluorescent 
protein, which allowed for sorting, gating and analysis of transduced cells among a background of 
uninfected cells. (C) Stable overexpression of either CDK4 or CDK6 increased the proliferation of PC3-
Lenti-AR cells. In addition, the increases in proliferation due to CDK4 and CDK6 overexpression 
remained partially sensitive to DHT treatment. For the relative cell numbers on treatment day 6, the 
significance differences among different overexpression groups (Control, CDK4, CDK6) and treatments 
(–DHT, +DHT) were determined by two-way ANOVA, followed by Tukey’s honest significant difference 
test. Box-Cox power transformation was used to stabilize variance and improve the validity of ANOVA. * 
P < 0.05. 
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Fig. 2.10 Model for AR-mediated growth suppression of HPr-1AR and PC3-Lenti-AR.  
(A) In the absence of androgen, cell cycle progression through the G1/S-phase transition and proliferation 
of HPr-1AR and PC3-Lenti-AR are promoted by basal expression of cyclin D1/2, CDK4/6, and 
CDKN1A. (B) Androgen signaling through AR increases CDKN1A expression and decreases the 
abundance and activity of cyclin D-CDK4/6 complexes by multiple mechanisms. Common mechanism 
for HPr-1AR and PC3-Lenti-AR: CDK4 and CDK6 are down-regulated through AR-mediated 
transcriptional repression. In addition, CDKN1A expression is up-regulated by AR-mediated 
transcriptional activation, and at elevated levels, CDKN1A inhibits CDK4/6-mediated phosphorylation of 
RB. Therefore, cell cycle progression through the G1/S-phase transition is delayed and proliferation is 
inhibited. HPr-1AR-specific mechanism: Cyclin D1 mRNA is down-regulated through an AR-mediated 
mRNA decay mechanism, whereas cyclin D2 pre-mRNA is down-regulated by AR-mediated 
transcriptional repression. 
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Fig. 2.11 Regulation of cyclin D, CDK, and CDKN1A mRNAs by androgen in HPr-1AR.  
After treatment with 10 nM DHT or vehicle control for various durations, total RNA was isolated from 
HPr-1AR cells, cDNA was synthesized by reverse transcription and the relative levels of cyclin mRNAs 
were quantified by QPCR analysis. (A) In time course experiments, cyclin D1 and D2 mRNAs were 
androgen-repressed at 8-48 hours (h). (B) CDK4 and CDK6 mRNAs were down-regulated at 16-48 hours, 
whereas CDKN1A mRNA was androgen-induced at 24-48 hours. Data represent the mean ± SEM, n=3. * 
P < 0.05. 
 
  
61 
 
 
 
Fig. 2.12 Inhibition of HPr-1AR cell proliferation in response to androgen and CDK selective 
inhibitor.  
HPr-1AR cells were treated with 10 nM of DHT or vehicle control and various concentrations of CDK 
selective inhibitor, PD0332991, and the relative number of viable cells was determined after 72 hours of 
treatment by quantification of ATP in metabolically active cells. Cell number increased for all treatments, 
however, HPr-1AR proliferation was decreased at 72 hours with increasing concentrations of PD0332991. 
By itself, PD0332991 inhibited HPr-1AR proliferation at doses ranging from 2-5 μM. However, the 
combined effects of PD0332991 and DHT on HPr-1AR proliferation were similar to DHT treatment 
alone. Data represent the mean ± SEM, n=4. * P < 0.05. 
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Fig. 2.13 AR-mediated destabilization of cyclin D1 mRNA in HPr-1AR.  
(A) Experimental design scheme depicts transcriptional inhibition by 5,6-
dichlororibofuranosylbenzimidazole (DRB), DHT treatment, and mRNA isolation. Cells were treated 
with transcription inhibitor, DRB, for 1 hour prior to treatment with 10 nM DHT or vehicle control, and 
total RNA was harvested at the indicated time points for quantification by QPCR. (B) Transcription of the 
PYGO2 control gene was unchanged by androgen, and the half-life of its mRNAs was unaffected. The 
half-life of cyclin D2 mRNA was unchanged by DHT treatment compared to vehicle control, whereas the 
cyclin D1 mRNA half-life was 5.5 hours in DHT-treated samples compared to 11.5 hours in control 
samples. Data represent the mean ± SEM, n=3. 
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Fig. 2.14 Transcriptional regulation of cyclin D1/2 pre-mRNAs by androgen in HPr-1AR.  
After treatment with 10 nM DHT or vehicle control for various durations, total RNA was isolated from 
HPr-1AR cells, cDNA was synthesized by reverse transcription and the relative levels of cyclin D1/2 pre-
mRNAs were quantified by QPCR analysis. In time course experiments, cyclin D1 pre-mRNA was 
unaffected by androgen treatment, whereas cyclin D2 pre-mRNAs declined substantially with DHT-
treatment. Cyclin D2 pre-mRNA was androgen-repressed to the greatest extent at 24-48 hours (h). Data 
represent the mean ± SEM, n=3. * P < 0.05. 
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Fig. 2.15 Overexpression of CDKN1A inhibits cell cycle progression in HPr-1AR.  
(A) Stable overexpression of CDKN1A was validated by immunoblot analysis. In comparison to parental 
HPr-1AR cells (black) and RFP control cells (blue), which have endogenous CDKN1A expression, HPr-
1AR cells that stably overexpress CDKN1A (orange) have increased (B) forward light scatter and (C) 
side light scatter values, suggesting that these cells have increased volume relative to the control cells. In 
comparison to (D) RFP control cells, (E) HPr-1AR cells that stably overexpress CDKN1A have increased 
DCV DNA intensity, which is consistent with increased DNA content in these cells. In addition, these 
cells display an abnormal cell cycle profile that interfered with accurate resolution of the cell cycle 
distribution. The integrated viral vectors used in these experiments also express red fluorescent protein, 
which allowed for gating and analysis of transduced cells among a background of uninfected cells. 
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Fig. 2.16 Regulation of CDK and CDKN1A mRNAs by androgen in PC3-Lenti-AR.  
After treatment with 10 nM DHT or vehicle control for various durations, total RNA was isolated from 
PC3-Lenti-AR cells, cDNA was synthesized by reverse transcription and the relative levels of CDK 
mRNAs were quantified by QPCR analysis. In time course experiments, CDK4 and CDK6 mRNAs were 
significantly androgen-repressed and CDKN1A mRNA was androgen-induced by 6-8 hours. Data 
represent the mean ± SEM, n=3. * P < 0.05. 
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Fig. 2.17 Overexpression of CDKN1A inhibits cell cycle progression in PC3-Lenti-AR.  
(A) Stable overexpression of CDKN1A was validated by immunoblot analysis. In comparison to parental 
PC3-Lenti-AR cells (black) and RFP control cells (blue), which have endogenous CDKN1A expression, 
PC3-Lenti-AR cells that stably overexpress CDKN1A (orange) have increased (B) forward light scatter 
and (C) side light scatter values, suggesting that these cells have increased volume relative to the control 
cells. In comparison to (D) RFP control cells, (E) PC3-Lenti-AR cells that stably overexpress CDKN1A 
have increased DCV DNA intensity, which is consistent with increased DNA content in these cells. In 
addition, these cells display an abnormal cell cycle profile that interfered with accurate resolution of the 
cell cycle distribution. The integrated viral vectors used in these experiments also express red fluorescent 
protein, which allowed for gating and analysis of transduced cells among a background of uninfected 
cells. 
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Chapter 3 
Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate 
Epithelial Cells 
Abstract 
Androgen receptor (AR) signaling is crucial to the development and homeostasis of the 
prostate gland, and its dysregulation mediates common prostate pathologies. The mechanisms 
whereby AR regulates growth suppression and differentiation of luminal epithelial cells in the 
prostate gland and proliferation of malignant versions of these cells have been investigated in 
human and rodent adult prostate. However, the cellular stress response of human prostate 
epithelial cells is not well understood, though it is central to prostate health and pathology. Here, 
we report that androgen sensitizes HPr-1AR and RWPE-AR human prostate epithelial cells to 
cell stress agents and apoptotic cell death. Although 5α-dihydrotestosterone (DHT) treatment 
alone did not induce cell death, co-treatment of HPr-1AR cells with DHT and an apoptosis 
inducer, such as staurosporine (STS), TNFα, or hydrogen peroxide, synergistically increased cell 
death in comparison to treatment with each apoptosis inducer by itself. We found that the 
synergy between DHT and apoptosis inducer led to activation of the intrinsic/mitochondrial 
apoptotic pathway, which is supported by robust cleavage activation of caspase-9 and caspase-3. 
Further, the dramatic depolarization of the mitochondrial membrane potential that we observed 
upon co-treatment with DHT and STS is consistent with increased mitochondrial outer 
membrane permeabilization (MOMP) in the pro-apoptotic mechanism. Interestingly, the synergy 
between DHT and apoptosis inducer was abolished by AR antagonists and inhibitors of 
transcription and protein synthesis, suggesting that AR mediates pro-apoptotic synergy through 
transcriptional regulation of MOMP genes. Expression analysis revealed that pro-apoptotic genes 
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(BCL2L11/BIM and AIFM2) were DHT-induced, whereas pro-survival genes (BCL2L1/BCL-
XL and MCL1) were DHT-repressed. Hence, we propose that the net effect of these AR-
mediated expression changes shifts the balance of BCL2-family proteins, such that androgen 
signaling sensitizes mitochondria to apoptotic signaling, thus rendering HPr-1AR more 
vulnerable to cell death signals. Our study offers insight into AR-mediated regulation of prostate 
epithelial cell death signaling. 
 
Introduction 
Androgen receptor (AR) signaling plays pivotal roles in the development, physiology, 
and pathology of the prostate gland. Upon binding its endogenous ligands, which include 
testosterone and 5α-dihydrotestosterone (DHT), a central function of the AR is to regulate gene 
expression as a transcriptional regulator [214,215]. In the nucleus, ligand-activated ARs 
associate with specific DNA sequences known as androgen response elements (AREs) and 
coordinate the recruitment of nuclear co-regulators, chromatin remodeling factors, and the 
transcriptional machinery, and thus regulate the transcription of target genes [13-17,216,217]. 
AR signaling is a central regulator of normal prostate development, cytodifferentiation, and 
homeostasis. Further, dysregulation of AR signaling is thought to be responsible for prostate 
cancer initiation and progression [123]. 
The oncogenic activity of AR has been intensively studied, mostly in prostate cancer. It is 
well documented that most prostate cancer cells express AR, and they are somewhat dependent 
on AR signaling for growth and proliferation [126-130,132-136,144]. In contrast to the 
oncogenic activity of AR in prostate cancer, AR signaling normally serves to restrain 
proliferation and stimulate differentiation and survival of luminal prostate epithelial cells in a 
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healthy prostate gland. In humans and rodents, the prostatic epithelium contains basal and 
luminal layers interspersed with rare neuroendocrine cells. Several groups have shown that 
intermediate cells and a subset of basal cells express low levels of AR [117,120,218,219]. 
Further, comparison of wild-type littermates to basal-ARKO mice revealed that AR knockout in 
the basal epithelial cells of the prostate increases the proliferation of these cells, including 
progenitor/intermediate cells, and may decrease the differentiation of these cells to luminal 
epithelial cells [120]. As intermediate cells differentiate and migrate to the luminal layer, AR 
expression increases. The abundant expression of AR in luminal epithelial cells is believed to 
suppress their proliferation and maintain their secretory function [158]. In addition, AR-mediated 
signaling in the mesenchyme/stroma and a paracrine signaling mechanism may also regulate 
survival of the luminal epithelial cells in the prostate [119,150]. 
While AR-regulated cell proliferation has been extensively studied, little is known about 
the cell stress response and apoptotic functions of AR signaling in prostate epithelial cells, 
though they are central to growth and homeostasis of the prostate gland. Upon exposure to 
various intra- or extra- cellular stressors (e.g., inflammatory factors, oxidative stressors, DNA 
damage agents, toxins, etc.), cells usually initiate multiple pathways to counteract the stimuli and 
repair the damage. A persistent stress response or irreversible cellular damage activates 
additional signaling pathways that ultimately lead to programmed cell death [220]. Apoptosis is a 
highly regulated signaling process that leads to cell death in an energy-dependent manner with 
characteristic hallmarks [79,221]. Central to apoptotic signaling is the activation of the extrinsic 
pathway or the intrinsic pathway, which are distinguished by the activation of different caspases. 
In the extrinsic pathway, death receptors of the tumor necrosis factor receptor superfamily at the 
plasma membrane sense extracellular death signaling ligands and activate initiator caspase-8 or -
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10. The active initiator caspases further cleave and activate executioner caspases-3, 6, and 7 [91-
93]. In the intrinsic pathway, multiple stress signals converge on the mitochondria and cause 
mitochondrial outer membrane permeabilization (MOMP), which leads to the release of pro-
apoptotic factors including cytochrome c, apoptosis-inducing factor mitochondrion-associated 
1/2 (AIFM1/2), and DIABLO. The released cytochrome c is bound by apoptotic peptidase 
activating factor 1 (APAF1) and assembled into the oligomeric apoptosome, which cleaves and 
activates initiator caspase-9 and the executioner caspases [94-97]. 
Importantly, the mitochondrial outer membrane and its permeability are crucial mediators 
of intrinsic and extrinsic apoptotic signaling. Typically, mitochondrial integrity is highly 
controlled by B-cell CLL/lymphoma 2 (BCL2) family proteins. The pro-apoptotic BCL2-
associated X protein (BAX) family proteins (including BAX, BCL2-antagonist/killer 1 (BAK), 
and BCL2-related ovarian killer (BOK)) mainly function at the mitochondrial membrane. The 
oligomerization of pro-apoptotic proteins BAX and BAK forms holes at the mitochondrial 
surface and thus causes the release of pro-apoptotic factors [99]. The pro-survival BCL2 family 
proteins (including BCL2, BCL2L1/BCL-XL, myeloid cell leukemia 1 (MCL1), etc.) interfere 
with the pro-apoptotic BCL2 family proteins and therefore maintain mitochondrial membrane 
integrity [100]. BH-3 only proteins (including BID, BAD, BCL2L11/BIM, NOXA, PUMA, etc.) 
are also pro-apoptotic, since they interact with pro-survival BCL2 family proteins and prevent 
them from interfering with BAX and BAK [99]. Indeed, the stoichiometry of pro-survival and 
pro-apoptotic BCL2 family proteins is a main determinant of whether a cell will live or die 
[79,100]. 
AR signaling plays a central role in prostate epithelial homeostasis, which is dependent 
upon the net balance of cell division and turnover. In a previous study, we defined a growth 
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suppression mechanism whereby AR-mediated down-regulation of cyclin D-CDK4/6 complexes 
inhibits cell cycle progression of HPr-1AR human prostate epithelial cells [222]. However, AR 
signaling and the apoptotic stress response of human prostate epithelial cells are not well 
understood, though they are central signaling pathways that have been implicated in the death of 
these cells and the regulation of prostate homeostasis and pathology. Importantly, the activation 
of AR signaling in HPr-1AR cells does not induce apoptosis under optimized culture conditions 
[165,222], which is consistent with the role that AR signaling serves to maintain homeostasis in 
the prostate through epithelial cytodifferentiation and growth suppression [119,120,149,158]. To 
further understand AR signaling in the context of the cell stress response, we hypothesized that 
AR signaling would promote turnover of stressed and damaged cells due to its homeostatic 
maintenance function in normal prostate epithelial cells. We investigate this hypothesis in the 
present study using various cell stress agents. 
Here, we demonstrate that AR activation sensitized human prostate epithelial cell lines 
HPr-1AR and RWPE-AR to apoptotic cell death in response to several cell stress agents, 
including staurosporine (STS), tumor necrosis factor-alpha and cycloheximide (TNFα+CHX), 
and hydrogen peroxide (H2O2). Interestingly, the mechanism responsible for the androgen-
sensitized cell death in HPr-1AR is distinct from the mechanism of AR-mediated growth 
suppression that we described previously [222]. We found that mitochondria play a central role 
in androgen-sensitized cell death, and AR-mediated up-regulation of pro-apoptotic genes 
(BCL2L11/BIM and AIFM2) and down-regulation of pro-survival genes (BCL2L1/BCL-XL and 
MCL1) may be responsible for the decreases in mitochondrial potential that we measured. Taken 
together, these data support the hypothesis that AR-mediated gene expression changes shift the 
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balance of BCL2-family proteins, such that androgen signaling sensitizes mitochondria to 
apoptotic signaling, thus rendering HPr-1AR more vulnerable to cell stress and death signals. 
 
Materials and Methods 
Cell culture and reagents 
Cell lines HPr-1AR and HPr-1 were gifts from Patrick Ming-Tat Ling (University of 
Hong Kong) [165]. RWPE-AR and RWPE-FG9 (AR-negative control line) were generated by 
lentiviral transduction of an RWPE-1 clone [223], lacking AR protein expression, as described in 
Higgins et al. and were gifts from Diane Robins (University of Michigan Medical School) [224]. 
HPr-1AR, HPr-1, RWPE-AR, and RWPE-FG9 cells were grown as described [36,222,224] in 
keratinocyte serum free medium (17005-042, Invitrogen, Carlsbad, CA) without androgen 
supplementation and a humidified 5% CO2 atmosphere at 37°C. Cells were treated in growth 
medium with 5 μM CDK4/6 kinase inhibitor, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-
piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one 2-hydroxy-ethanesulfonic 
acid (1:1), PD0332991, PZ0199, Sigma-Aldrich, St. Louis, MO) or 0-10 nM AR agonist (5α-
dihydrotestosterone, DHT) in the presence or absence of AR antagonist, 10 μM 2-
hydroxyflutamide (OHF, H4166, Sigma-Aldrich) or 5-10 μM enzalutamide (ENZ, S1250, 
Selleckchem, Houston, TX), for the indicated duration. To induce apoptotic cell death, cells were 
further treated with 0.5-2 μM staurosporine (STS, 1285, Tocris, United Kingdom), 40 ng/mL 
tumor necrosis factor-alpha (TNFα, 210-TA, R&D Systems, Minneapolis, MN) and 2 μg/mL 
cycloheximide (CHX, C7698, Sigma-Aldrich), 200 μM hydrogen peroxide (H2O2, H325, Fisher 
Scientific), or 5 µM (-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-
binaphthalene]-8,8'-dicarboxaldehyde (AT101, 3367, Tocris Bioscience, Bristol, United 
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Kingdom) for the indicated duration. Cells were co-treated with 20 μg/ml 5,6-
dichlororibofuranosylbenzimidazole (DRB, D1916, Sigma-Aldrich) as described [222] to inhibit 
transcription and 25-50 μg/mL CHX to inhibit protein synthesis.  
 
Measurement of relative ATP concentrations 
The relative ATP levels available for biochemical processes in metabolically active cells 
were quantified using the CellTiter-Glo Luminescent Cell Viability Assay Kit (G7571, Promega, 
Madison, WI) as described [222]. Briefly, cells were exposed to 50% CellTiter-Glo Reagent in 
PBS and luminescence was analyzed using a VICTOR X5 plate reader (2030-0050, PerkinElmer, 
Waltham, MA). 
 
Annexin V and propidium iodide (PI) staining 
Apoptosis assays were performed using Alexa Fluor 488- or Pacific Blue-conjugated 
Annexin V/Dead Cell Apoptosis Kit (A13201 or A35122, Molecular Probes, Crand Island, NY), 
as instructed by the manufacturer, and quantified using an LSR II flow cytometer (Becton 
Dickinson Biosciences, Franklin Lakes, NJ) and FCS Express 4 Flow software (De Novo 
Software, Glendale, CA). Briefly, cells were collected, washed with cold PBS, and resuspended 
in 100-150 μL of binding buffer. Cells were stained with 5-7.5 μL of annexin V and 1-1.5 µL of 
100 µg/mL PI at room temperature for 15 min and then diluted with 250-400 μL of binding 
buffer. The intensities of fluorescent annexin V and PI stained cells were quantified by flow 
cytometry at 450 nm, 530 nm and 695 nm, respectively. The percentages of cells undergoing 
apoptosis were determined by dual color analysis, which allowed us to distinguish three subsets 
of cells: viable live cells (annexin V-negative and PI-negative), early apoptotic cells (annexin V-
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positive and PI-negative), and late apoptotic or necrotic cells (annexin V-positive and PI-
positive) [225,226]. 
 
Immunoblot analysis 
Immunoblots were performed to determine the relative levels of cleaved and activated 
caspase-8, caspase-9, and caspase-3 as well as the relative expression of BCL2L11/BIM, 
BCL2L1/BCL-XL, and MCL1 at various time points after the indicated treatment. Cells were 
washed with PBS and harvested in 200-600 μL of RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 1% sodium deoxycholate, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM NaF and protease inhibitors). Total cell 
lysates containing equal amounts of protein were subjected to 4-20% mini-TGX gel (456-1096, 
Bio-Rad, Hercules, CA) electrophoresis for 35 min at 200 V and then transferred to PVDF 
membranes for 2 or more hours at 50 V. Non-specific binding was blocked by incubation of the 
membranes in a solution containing 5% non-fat milk in TBST buffer (20 mM Tris-HCl (pH 7.5), 
150 mM NaCl and 0.1% Tween-20). Blots were incubated with rabbit antibodies raised against 
GAPDH, caspase-3, cleaved caspase-3, caspase-8, caspase-9, BCL2L11/BIM, BCL2L1/BCL-
XL, and MCL1 (2118, 9662, 9664, 9496, 9502, 2933, 2764, and 5453, Cell Signaling, Danvers, 
MA) overnight, followed by incubation with anti-rabbit IgG, horseradish peroxidase (HRP)-
linked antibody (7074 Cell Signaling). The blots were visualized using Pierce ECL Western 
Blotting Substrates (32106/34080/34096, Thermo, Rockford, IL) and HyBlot CL 
Autoradiography Film (E3018, Denville Scientific, Metuchen, NJ). Films were scanned and 
Image J software was used to quantify protein expression relative to GAPDH. 
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Mitochondrial membrane potential assay 
The mitochondrial membrane potential of treated HPr-1AR cells was detected using the 
MitoProbe JC-1 Assay Kit (M34152, Molecular Probes, Crand Island, NY), as instructed by the 
manufacturer, and quantified by flow cytometry. Cells were harvested and resuspended in 1 mL 
warm PBS. JC-1 dye was added to a final concentration of 5 µM. In addition, the positive control 
group was exposed to 100 µM carbonyl cyanide 3-chlorophenylhydrazone (CCCP), which is a 
proton ionophore that has been shown to uncouple oxidative phosphorylation in mitochondria 
[227,228]. Cells were then incubated in a humidified 5% CO2 atmosphere at 37°C for 20 
minutes. After two washes with PBS at 37°C, cells were resuspended in 1 mL PBS, and the 
intensities of fluorescent JC-1 stained cells were quantified by flow cytometry at 530 nm and 585 
nm. 
 
RNA isolation, reverse transcription, and real-time quantitative polymerase chain 
reaction (QPCR) 
Total RNA was extracted from the cells using Qiagen RNeasy Mini Kit (74106, Qiagen) 
with on-column DNase treatment (79254, Qiagen). Random-primed cDNA was prepared from 2 
μg of total RNA using the ProtoScript First Strand cDNA kit (E6300L, New England Biolabs, 
Ipswich, MA) and diluted 5-fold in water. One μL of diluted cDNA was used as template for 
QPCR using StepOnePlus Real-Time PCR System (Applied Biosystems, Grand Island, NY). 
Primers were designed using Primer3 (http://frodo.wi.mit.edu) and those that efficiently 
amplified [174] single products of the expected size were used for QPCR. Primers for QPCR 
amplicons are in Supporting Information (Table 3.1). The QPCR was achieved using the 
following method: a denaturation and polymerase activation step at 94°C for 1 min and then 40 
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cycle consisting of 94°C for 10 s, 57°C for 10 s, and 72°C for 20 s. Data were analyzed using the 
comparative threshold cycle (Ct) method [176] and multiple control genes, including ADAM15, 
PYGO2, TBP and GAPDH, which are not regulated by androgen or AR. Following 
normalization to control gene cDNA levels, which is reflected in the ΔCt values, the relative 
quantification (RQ) of the fold change for each treatment compared to reference control was 
determined using the following equation: RQ = 2(–ΔCt) / 2(–ΔCt reference). The mean of the 
log2 RQ and standard error of the mean (SEM) were plotted. 
 
Statistical analysis 
Unless otherwise specified, the significance differences between two treatment groups 
were determined by Student’s t-test, whereas the differences among multiple groups were 
determined by analysis of variance (ANOVA) using a randomized complete block design, 
followed by Tukey's honest significant difference test. To improve the validity of ANOVA, non-
normal or heteroscedastic data were normalized using the corresponding basal level or 
transformed using variance stabilization transformation methods (e.g., arcsine transformation and 
Box-Cox power transformation) before ANOVA [177]. A significance level of 0.05 was applied 
during data analysis, and different significance levels have been indicated using different 
lowercase letters. In addition, the ANOVA data from the analysis of the viable live cells (annexin 
V-negative and PI-negative, gray bars) that were quantified by flow cytometry are provided in 
Supporting Information (Table 3.2). We have indicated the 95% confidence intervals of the main 
and interaction effects. 
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Results 
Androgen and staurosporine synergize to decrease the relative ATP 
concentration of HPr-1AR cells 
The mechanism whereby AR influences the proliferation and survival of prostate 
epithelial cells has been investigated. Our group and Ling et al. have previously reported that 
androgens inhibit the proliferation of HPr-1AR, a human prostate epithelial cell line stably 
expressing wild-type AR (Fig. 3.8), without affecting cell survival under optimized culture 
conditions [165,222]. However, the cellular stress response of human prostate epithelial cells is 
not well understood. To investigate whether androgen signaling may modulate the stress 
response of prostate epithelial cells, we treated HPr-1AR cells with 0-10 nM 5α-
dihydrotestosterone (DHT) for 18 hours followed by 1 μM staurosporine (STS), a widely-used 
cell stress agent and apoptosis inducer [229], or DMSO vehicle control and then measured 
relative ATP concentrations at 24 hours. A two-way analysis of variance (ANOVA) model was 
applied to quantify the effects of DHT and STS alone as well as any interaction between DHT 
and STS. In dose-response experiments (Fig. 3.1A), 0.1 to 10 nM DHT treatments modestly 
decreased the relative ATP concentration (8% to 14%) at 24 hours due to DHT-induced growth 
suppression of HPr-1AR cells as previously described [222]. Meanwhile, STS treatment by itself 
decreased the relative ATP levels by 40%. Interestingly, DHT and STS co-treatment 
significantly decreased ATP concentrations 8% to 21% beyond the additive effects of DHT and 
STS treatments (p<0.001), indicating that DHT and STS synergize to reduce the relative ATP 
levels in HPr-1AR. In time-course experiments of HPr-1AR cells pre-treated with DHT 
compared to vehicle as a control, the sensitizing effect of DHT on STS-induced ATP depletion 
was evident at 3, 6, and 9 hours, decreasing ATP levels by 40-76% (Fig. 3.1B). In addition, the 
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synergistic interaction between DHT and STS was suppressed by AR antagonists, enzalutamide 
(ENZ) (Fig. 3.1C) and 2-hydroxyflutamide (OHF) (Fig. 3.9). Hence, the androgen-sensitized 
depletion of ATP concentration in HPr-1AR is mediated by AR and may lead to a synergistic 
decrease of viability. 
Further, to assess whether the synergistic depletion of ATP concentration by DHT and 
STS is due to a prolonged G1 interval in the cell cycle and growth suppression [222], we treated 
HPr-1AR cells with 5 μM PD0332991, a selective inhibitor of CDK4/6 kinase activity, to mimic 
the inhibitory effect of DHT on HPr-1AR cell cycle progression and growth. PD0332991 by 
itself decreased the relative ATP concentration by 20% due to growth suppression, and STS by 
itself decreased ATP concentration and, possibly, viability by 35% (Fig. 3.1D). However, the co-
treatment group showed no synergistic effect. Rather, the interaction between STS and 
PD0332991 in an additive model was +12% (Fig. 3.1D), suggesting an antagonistic effect 
between STS and PD0332991. Nonetheless, the synergy of DHT and STS on ATP depletion is 
not dependent on growth suppression. Hence, the mechanism whereby AR sensitizes HPr-1AR 
cells to STS-induced ATP depletion and, possibly, cell death is distinct from AR-mediated 
growth suppression. 
 
Androgen sensitizes HPr-1AR and RWPE-AR to apoptotic cell death 
To determine whether the synergistic decrease of ATP concentration in HPr-1AR cells 
co-treated with DHT and STS was due to an increase in programmed cell death, we performed 
annexin V and propidium iodide (PI) staining, which was quantified using flow cytometry. 
Healthy live cells stain poorly with annexin V and PI. Early apoptotic cells that expose more 
phosphatidylserine at the surface of their intact plasma membrane are labeled by annexin V but 
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not PI, whereas the nuclei of late apoptotic cells with compromised membrane integrity are 
labeled by annexin V and PI. In the absence of STS treatment, DHT by itself did not induce HPr-
1AR cell death (Fig. 3.2A-B, Table 3.2), which is consistent with a previous study using terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay [165]. STS by itself 
increased the apoptotic population, albeit not significantly. However, DHT and STS co-treatment 
synergistically increased the proportion of dead cells by 35% compared to STS treatment alone. 
Further, ENZ suppressed the synergistic interaction between DHT and STS, which is evident 
from the rescue of the live cell population. Consistent with the synergistic effect of DHT and 
STS being AR-mediated, control experiments using the AR-negative parental cell line HPr-1 
(Fig. 3.8) revealed a lack of synergy between DHT and STS (Fig. 3.10, Table 3.2). 
To test whether the DHT-sensitized cell death is limited to STS-induced apoptosis, we 
treated HPr-1AR with other cell stress agents, including tumor necrosis factor-alpha and 
cycloheximide (TNFα+CHX), hydrogen peroxide (H2O2), and AT101, which can induce 
apoptosis through different mechanisms that are distinct from STS [230-234]. Although DHT by 
itself did not induce cell death, co-treatment of any of these cell stress agents with DHT 
significantly increased the proportions of early and late apoptotic cells. DHT co-treatment 
potentiated TNFα+CHX-induced apoptosis by 10% (Fig. 3.2C, Table 3.2), H2O2-induced cell 
death by 33% (Fig. 3.2D, Table 3.2), and AT101-induced apoptosis by 15% (data not shown). 
Thus, AR signaling in HPr-1AR is pro-apoptotic in the sense that it sensitizes HPr-1AR cells to 
apoptotic death in response to cell stress agents. 
In addition, we investigated the extent to which androgen sensitizes RWPE-AR cells to 
programmed cell death. RWPE-AR is a clone of the RWPE-1 human prostate epithelial cell line 
[223] that stably expresses wild-type AR (Fig. 3.8). DHT by itself did not induce RWPE-AR cell 
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death (Fig. 3.2E, Table 3.2), which is consistent with our findings in HPr-1AR (Fig. 3.2A-B). 
STS by itself significantly increased the proportion of apoptotic RWPE-AR cells (Fig. 3.2E). 
DHT and STS co-treatment synergistically increased the proportion of dead cells by 10% 
compared to STS treatment alone. Further, ENZ abolished the synergistic interaction between 
DHT and STS, which is demonstrated by the complete rescue of the live cell population. 
Consistent with the synergy of DHT and STS being AR-mediated, additional control 
experiments using AR-negative RWPE-FG9 control cells (Fig. 3.8) showed an absence of 
synergy between DHT and STS (Fig. 3.10, Table 3.2). Indeed, the HPr-1AR and RWPE-AR data 
reveal that physiologic levels of DHT sensitize benign, AR-expressing human prostate epithelial 
cells to programmed cell death. 
To confirm that androgen sensitizes HPr-1AR to apoptosis rather than other types of cell 
death, we examined the proteolytic cleavage of caspases, which become activated and serve as a 
hallmark of the later stages of apoptosis. In accordance with the annexin V and PI staining 
results, DHT treatment by itself did not increase the cleavage of initiator caspase-9 or 
executioner caspase-3 (Fig. 3.3A). However in combination with STS, DHT robustly increased 
cleaved caspase-9 and caspase-3 levels. In time course experiments, DHT and STS co-treatment 
rapidly enhanced the levels of cleaved caspase-9 and caspase-3 (within 4 hours), whereas STS 
treatment by itself had little or no effect on the cleavage of these caspases (Fig. 3.3A). 
Importantly, the DHT- and STS-enhanced cleavage of caspase-9 and caspase-3 was completely 
blocked by AR antagonist, ENZ (Fig. 3.3B). In addition, activation of extrinsic apoptotic 
signaling using TNFα+CHX led to cleavage and activation of initiator caspase-8 (Fig. 3.3C). 
Although synergistic activation of caspase-8 was not detected in cells co-treated with DHT and 
TNFα+CHX, DHT synergized with TNFα+CHX to robustly enhance cleavage of caspase-9 and 
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caspase-3 in HPr-1AR cells (Fig. 3.3C). In additional time course experiments, DHT and H2O2 
co-treatment rapidly increased the levels of cleaved caspase-3 (within 4 hours), whereas H2O2 
treatment by itself had little or no effect on caspase-3 cleavage (Fig. 3.3D). Consistent with the 
HPr-1AR data, DHT and STS co-treatment robustly enhanced the levels of cleaved caspase-3 in 
RWPE-AR (within 5 hours), whereas STS treatment by itself modestly increased caspase-3 
cleavage (within 10 hours) (Fig. 3.3E). Taken together, the annexin V and PI staining data and 
the caspase activation data demonstrate that AR-mediated androgen signaling sensitizes HPr-
1AR and RWPE-AR cells to apoptosis through caspase activation, which may involve the 
intrinsic mitochondrial pathway. 
 
Androgen and staurosporine synergize to induce mitochondrial depolarization in 
HPr-1AR 
Mitochondria play crucial roles in cell survival and death decisions. Mitochondrial outer 
membrane permeabilization (MOMP) and the release of cytochrome c and other pro-apoptotic 
molecules are early signaling events that lead to activation of the intrinsic apoptotic pathway and 
they may also be activated by the extrinsic apoptotic pathway. To determine whether androgen 
sensitizes HPr-1AR to undergo apoptosis by inducing MOMP, we performed JC-1 staining 
followed by flow cytometry analysis of treated HPr-1AR cells. The dual-fluorescent dye, JC-1, 
accumulates in mitochondria and serves as a sensor of mitochondrial membrane potential, which 
is an important parameter of mitochondrial health that declines rapidly during MOMP. 
Normal cells with intact mitochondria exhibit strong red and green fluorescence, display 
various red to green ratios, and thus form a wide bell-shaped distribution in a histogram plot 
(Fig. 3.4A). In contrast, cells with depolarized mitochondria due to treatment with 100 µM 
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carbonyl cyanide 3-chlorophenylhydrazone (CCCP), which is a proton ionophore that has been 
shown to uncouple oxidative phosphorylation in mitochondria [227,228], exhibit low red 
fluorescence, display uniformly low red to green ratios, and form a left-shifted spike in a 
histogram plot (Fig. 3.4B). DHT treatment did not increase mitochondrial depolarization (Fig. 
3.4C) and STS treatment by itself modestly increases mitochondrial depolarization, as evidenced 
by a sub-peak close to zero in the histogram (Fig. 3.4D). Remarkably, DHT and STS co-
treatment substantially increased the proportion of cells with depolarized mitochondria by 4-fold 
or more (Fig. 3.4F), which resulted in a left-shifted spike in the histogram (Fig. 3.4E), 
approximating the shape of the positive control sample (compare Figs. 4B and 4E). Since the 
mitochondrial depolarization is usually a direct outcome of MOMP, these results indicate that 
AR-sensitized apoptosis in HPr-1AR involves increased mitochondrial permeability. 
 
Transcription and protein synthesis are necessary for androgen-sensitized 
apoptosis of HPr-1AR 
The androgen-sensitized apoptosis in HPr-1AR was suppressed by AR antagonists (Figs. 
2A-B and 3B), implicating AR in this process. Previous studies have reported that AR displays 
pro-apoptotic function; although the proposed mechanisms differ between these studies, a 
common assertion is that the pro-apoptotic function of AR is independent of the transcriptional 
regulation function of AR [235-239]. To investigate whether the AR-mediated apoptotic 
signaling is dependent on transcription, we blocked transcription in HPr-1AR cells using 5,6-
dichlororibofuranosylbenzimidazole (DRB). HPr-1AR cells were treated with 1 nM DHT or 
vehicle control in the absence or presence of 20 μg/mL DRB for 16 hours, and then co-treated 
with 1 µM STS or vehicle control for 4 hours to induce apoptosis. To assess cell death, we 
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performed annexin V and PI staining, which was quantified using flow cytometry. DRB 
treatment significantly suppressed the androgen-sensitized apoptosis of HPr-1AR (Fig. 3.5A, 
Table 3.2). In addition, we blocked protein synthesis in HPr-1AR using 25 μg/mL CHX in place 
of DRB and assessed cell death by quantifying annexin V and PI staining. Similar to DRB, CHX 
treatment significantly suppressed the androgen-sensitized apoptosis of HPr-1AR (Fig. 3.5B, 
Table 3.2). Immunoblot analysis of caspase-3 cleavage revealed that CHX by itself modestly 
increased caspase-3 cleavage in the presence of STS. Further, inhibition of transcription by DRB 
or protein synthesis by CHX, robustly suppressed the synergy between DHT and STS in HPr-
1AR. (Fig. 3.5C). Taken together, these data demonstrate that transcription and protein synthesis 
are necessary for androgen-sensitized apoptosis in HPr-1AR. 
 
AR-mediated transcriptional regulation of apoptotic genes in HPr-1AR 
To identify genes responsible for androgen-sensitized MOMP in HPr-1AR and to further 
investigate whether androgen-sensitized apoptosis of these cells is dependent on the 
transcriptional regulation function of AR, we interrogated the expression of genes implicated in 
the mitochondrial apoptotic pathway using QPCR. In HPr-1AR, the mRNA levels of several 
apoptotic genes changed significantly with DHT treatment (Fig. 3.6A). Specifically, several 
BCL2 family genes were androgen-responsive, including the DHT-induced pro-apoptotic genes 
(BCL2L11/BIM and BOK) and the DHT-repressed pro-survival genes (BCL2A1, 
BCL2L1/BCL-XL, and MCL1) (Fig. 3.6A-B). In addition, transcripts for the AIFM2 gene, 
which codes for a pro-apoptotic protein that is released from the mitochondria into the cytoplasm 
upon MOMP, and the APAF1 gene, which codes for an apoptosis initiator protein that binds 
cytochrome c and forms the oligomeric apoptosome, were DHT-induced. The androgenic 
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regulation of pro-apoptotic gene (BCL2L11/BIM and AIFM2) transcripts and pro-survival gene 
(BCL2L1/BCL-XL and MCL1) transcripts was blocked by co-treatment with AR antagonist 
ENZ, implicating AR in their transcriptional regulation (Fig. 3.6B). Further, immunoblot 
analysis confirmed that the expression of pro-apoptotic BCL2L11/BIM, was up-regulated, and 
pro-survival factors, BCL2L1/BCL-XL and MCL1, were down-regulated (Fig. 3.6C). Taken 
together, these results identify androgen-responsive genes (BCL2L11/BIM, AIFM2, 
BCL2L1/BCL-XL, and MCL1), which are known to express apoptotic regulators, as candidate 
targets for AR-mediated transcriptional regulation. 
 
Discussion 
We investigated the functional role of AR in the apoptotic stress response of human 
prostate epithelial cells. We determined that AR signaling alone does not induce HPr-1AR and 
RWPE-AR cell death, rather it exerts pro-apoptotic activity that sensitizes these human prostate 
epithelial cells to apoptotic cell death in response to various cell stress agents. Our results 
indicate that AR-mediated regulation of mitochondrial membrane integrity plays a central role in 
this process. BCL2 family proteins function as “molecular switches” that fine-tune mitochondrial 
membrane permeability. Our study shows that DHT up-regulates the expression of pro-apoptotic 
genes (including BCL2L11/BIM and AIFM2) and down-regulates the expressions of pro-
survival genes (including BCL2L1/BCL-XL and MCL1) indicating that AR signaling may exert 
its pro-apoptotic activity on mitochondrial membrane permeability by altering the expression of 
BCL2 family genes. Notably, the regulation of BCL2 family gene expression is modest, which 
may explain why DHT treatment alone does not induce apoptosis in HPr-1AR. However, the 
multi-target regulation of BCL2 family proteins by AR signaling may sufficiently stress the 
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mitochondria toward a pro-apoptotic state (i.e., leaky outer membrane) and decrease the 
threshold for other cell stress agents to deliver the deathblow through enhanced permeabilization 
of the mitochondrial outer membrane above the threshold for caspase activation and apoptosis 
(Fig. 3.7). 
 
AR action in non-malignant prostate epithelial cells 
AR signaling plays crucial roles in prostate homeostasis, which involves balancing cell 
division, differentiation, and death. Studies in vivo using mice lacking AR in cytokeratin-5 
expressing cells of the prostate basal epithelial layer have demonstrated that AR signaling 
suppresses basal epithelial and progenitor cell proliferation and drives basal epithelial cells 
toward a more differentiated state [119,120]. Further, AR normally promotes cytodifferentiation 
and suppresses proliferation of intermediate epithelial cells [120] and maintains the secretory 
function of differentiated luminal epithelial cells [119]. In addition, androgen activation of AR 
expressed in the basal, intermediate, and luminal epithelial cells from rodents and humans 
invariably suppresses cell cycle progression and proliferation of these cells [120,158,165,222]. 
Previously, we described a mechanism of androgen-suppressed proliferation of HPr-1AR 
cells that is AR-mediated and involves down-regulation of cyclin D1/2-CDK4/6 complexes and 
up-regulation of cell cycle inhibitor, CDKN1A/p21 [222]. In comparison to quiescent cells, 
proliferating cells have been suggested to be more susceptible to apoptosis. The activation of 
cyclins and CDKs are positively correlated with the onset of apoptosis [240-243], whereas, the 
up-regulation of cell cycle inhibitors has been suggested to decrease susceptibility to apoptosis 
[242,244,245]. Based on these previous studies, the anti-proliferative effect of androgen in HPr-
1AR and the expression changes of the cyclins, CDKs, and CDKN1A in response to androgen 
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were expected to suppress apoptosis in HPr-1AR. However, we found that activation of AR 
signaling sensitizes HPr-1AR and RWPE-AR cells to apoptosis in response to cell stress agents. 
Furthermore, our results using PD0332991, which inhibits CDK4/6-mediated cell cycle 
progression, demonstrates that the anti-proliferative function of AR signaling is distinct from its 
pro-apoptotic function in HPr-1AR (Fig. 3.1D). 
 
Apoptotic functions of AR signaling 
While AR-mediated growth suppression has been well-studied, little is known about the 
apoptotic functions of AR in the prostate epithelium. Previous studies have revealed that 
androgen treatment does not induce apoptosis of human or rodent prostate epithelial cells 
[158,165,222]. As the experiments described in these studies were conducted under optimized 
culture conditions and in the absence of cellular stress, they primarily focused on defining the 
role of AR signaling in growth suppression and differentiation rather than its role in the cell 
stress response. To further investigate the apoptotic functions of AR, we challenged HPr-1AR 
cells with several different cell stress agents. Surprisingly, HPr-1AR cells pre-treated with DHT 
displayed hypersensitivity and synergy to several apoptosis inducers, including STS, 
TNFα+CHX, H2O2, and AT101 (Figs. 2-3). Importantly, these cell stress agents are known to 
induce cell death through different mechanisms. STS, H2O2, and AT101 stimulate the intrinsic 
apoptotic pathway by non-selective inhibition of protein kinases [229], oxidative stress and 
damage [232-234], and suppression of pro-survival BCL2 family genes [230], respectively; 
whereas, TNFα stimulates the extrinsic apoptotic pathway by activation of TNF family death 
receptors located at the cell surface [231]. Hence, the androgen-sensitized apoptosis in HPr-1AR 
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appears to be a common response to cell stress agents and further implicates crosstalk between 
AR and apoptotic signaling pathways, rather than simple cytotoxic effects. 
In addition to their central role in intrinsic apoptotic signaling pathways, mitochondria 
are also downstream targets of extrinsic signaling pathways, and therefore serve as apoptotic 
signaling hubs. Our finding that androgen sensitizes HPr-1AR cells to intrinsic and extrinsic 
apoptosis led us to question whether the putative crosstalk between AR and apoptotic signaling 
pathways involves mitochondria. The JC-1 staining profile showed a significant trend whereby 
DHT and STS synergistically increase mitochondrial membrane permeability (Fig. 3.4), 
suggesting that DHT renders mitochondria more vulnerable to intrinsic apoptotic stimuli and 
MOMP. Meanwhile, the activation of caspase-9, a hallmark of intrinsic apoptotic signaling, was 
detected after co-treatment with DHT and TNFα+CHX (Fig. 3.3). Activation of intrinsic 
signaling following activation of extrinsic signaling indicates that the androgen-sensitized 
apoptosis of HPr-1AR is correlated with increased mitochondrial outer membrane permeability. 
This conclusion is also consistent with our gene expression analysis. Three pro-survival genes 
(BCL2A1, BCL2L1/BCL-XL, and MCL1) were DHT-repressed and four pro-apoptotic genes 
(BCL2L11/BIM, AIFM2, BOK, and APAF1) were DHT-induced (Fig. 3.6). The net expression 
changes in the BCL2 family gene products are likely sufficient to increase the probability of hole 
formation at the mitochondrial surface and therefore lower the threshold for MOMP. The 
moderate regulation of these BCL2 family genes may be the reason that DHT treatment alone 
fails to induce MOMP and apoptosis in HPr-1AR. 
AR promoted cell death has been described in several prostate cancer cell lines. 
Androgen-induced apoptosis, characterized by DHT induced-cell cycle arrest and DNA 
fragmentation, has been reported for PC-3 cells that stably overexpressed AR [166]. However, 
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more recent studies have shown that androgen inhibits the proliferation of AR-expressing PC-3 
cells without inducing cell death [154]. In LNCaP-104-R1, which are castration-resistant prostate 
cancer cells that express mutant AR, AR signaling has been suggested to promote ultraviolet or 
STS-induced apoptosis via BAX protein translocation from the cytoplasm to mitochondria [246]. 
Additional studies elucidated that the pro-apoptotic function of the AR is primarily mediated by 
the proteasome, which generates N-terminal fragments of the AR that may decrease the basal 
expression of CDKN1A (p21) through a transcription-independent mechanism. Further, 
blockade of AR degradation or overexpression of BCL2 was found to suppress the pro-apoptotic 
function of AR in LNCaP-104-R1 [238,239]. Such a mechanism is not consistent with the 
androgen-sensitized apoptosis of HPr-1AR because we have shown previously that CDKN1A is 
a DHT-induced gene in HPr-1AR [222]. In AR-negative DU145 cells, co-expression of RB and 
AR reportedly induces intrinsic apoptosis that is dependent on pro-apoptotic proteins, BAX and 
BAK. However, the apoptotic effect is dependent on RB-mediated transactivation of AR rather 
than AR ligand binding [247]. In polyglutamine (polyQ)-expanded AR-induced cell death, the 
polyQ fragments, generated by caspase-3 cleavage, have been suggested to mediate their 
cytotoxic effect by BAX-dependent intrinsic pathway activation [235,237]. Nonetheless, nearly 
all of these apoptotic effects of AR have been suggested to be mediated by “non-genomic” AR 
function outside of the nucleus [248]. Therefore, the mechanism whereby androgen sensitizes 
HPr-1AR cells to death differs from the previous reports in two significant aspects. First, the pro-
apoptotic AR function depends on agonist binding, as AR antagonists abolished the synergistic 
interaction between DHT and STS (Figs. 1-3). Second, AR exerts pro-apoptotic function through 
transcriptional regulation, since transcriptional inhibition robustly suppressed the synergy 
between DHT and STS (Fig. 3.5). 
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Insights for prostate cancer 
In contrast with the anti-proliferative and pro-apoptotic roles of AR in non-malignant 
prostate epithelial cells, most prostate cancer cells express AR and are somewhat dependent on 
AR signaling for growth and proliferation [126-130,132-136,144,248]. In these cells, pro-
survival signaling by AR has been suggested to prevent apoptosis through multiple mechanisms 
[190,244,249-253]. Therefore, androgen deprivation therapy (ADT) has been applied as a first-
line treatment for metastatic prostate cancer and the beneficial effects are evidenced by rapid and 
dramatic tumor regression [147,254,255]. However, nearly all prostate cancers treated with ADT 
become resistant to its effects over a period of months to years, as a subset of the malignant cells 
eventually adapts to survive the ADT-induced environment and emerges as castration-resistant 
prostate cancer (CRPC). 
Our results in HPr-1AR suggest a mechanism that may, in part, explain the development 
of CRPC. From tumor histology studies, it is well known that prostate cancer cells most closely 
resemble secretory prostate epithelial cells, however recent biomarker and genomic studies have 
revealed that prostate cancers are commonly multifocal and consist of heterogeneous cell 
populations [256,257]. Recent studies have demonstrated that both basal and luminal epithelial 
cells can initiate prostate cancer in mouse models [258-261]. Importantly, AR expression in 
benign basal/progenitor cells is known to be low or undetectable, which is consistent with a lack 
of AR-mediated cytodifferentiation and growth suppression [120] and resistance to castration-
induced cell death. AR signaling may retain similar functional roles in prostate cancer stem 
progenitor (S/P) cells. As such, ADT may stimulate the proliferation and survival of these cells. 
Therefore, it is reasonable to speculate that distinct cell populations arise in prostate cancer, 
including a population that has become androgen-stimulated for growth and other populations 
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that are androgen-independent or androgen-suppressed for growth. While ADT may induce cell 
cycle inhibition and even death in the androgen-stimulated population, the drop of serum 
androgen levels may also loosen the brake imposed on the androgen-suppressed population, 
providing a selective advantage for these cells to survive, proliferate, and support tumor 
recurrence. In support of this, Zhifang et al. recently reported that AR activation suppressed the 
proliferation and tumorigenesis of S/P cells isolated from LNCaP prostate cancer cell line [262]. 
Although AR-mediated growth suppression of S/P cells remains to be confirmed in vivo, these 
results taken together with our results in HPr-1AR and RWPE-AR are consistent with cell-
specific roles of AR signaling in the prostate. Hence, the development of therapies that 
selectively inhibit the proliferative and anti-apoptotic AR activities while preserving the anti-
proliferative and pro-apoptotic AR activities may provide a beneficial outcome compared to 
systemic inhibition of AR signaling. 
 
AR-mediated transcriptional regulation of apoptosis-related genes 
The AR-sensitized apoptosis in HPr-1AR was blocked using AR antagonists and 
inhibitors of transcription and protein synthesis (Fig. 3.5), indicating that AR-regulated gene 
expression is necessary for the synergy of DHT and the cell stress agents. We interrogated 
apoptosis-related genes using QPCR to identify androgen-responsive genes that may play a role 
in AR-sensitized apoptosis. We found several androgen-responsive genes are putative AR-
regulated genes, whereas the vast majority of the apoptosis-related genes were unresponsive to 
androgen. Of the apoptosis-related genes with the greatest response to androgen, the pro-
apoptotic genes (BCL2L11/BIM, AIFM2, BOK, and APAF1) are DHT-induced, and the pro-
survival genes (BCL2A1, BCL2L1/BCL-XL, and MCL1) are DHT-repressed. Interestingly, 
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most of these androgen-responsive genes are BCL2 family genes, which are known to regulate 
mitochondrial membrane permeability, and the expression changes of these genes in response to 
androgen are consistent with pro-apoptotic AR activity in HPr-1AR. 
To further investigate whether these androgen-responsive genes may be regulated by AR, 
we searched for putative AR-occupied sites near these genes using the Hormone Receptor Target 
Binding Loci Database (HRTBLDb) [263] and ENCODE Consortium data [209]. The Massie et 
al. data in HRTBLDb using R1881-treated LNCaP cells reveal an AR-occupied region 81 kb 
downstream of the AIFM2 TSS as a putative site of AR regulation [43]. Since the closely related 
glucocorticoid receptor (GR) binds in vitro with similar affinity as AR to consensus sequences in 
the elementary half-sites GGTACAnnnTGTTCT [14,36], we also searched GR-occupied regions 
near these genes. The ENCODE Consortium data for dexamethasone-treated A549 cells identify 
multiple GR-occupied regions near all seven of the putative AR-regulated apoptosis-related 
genes [209]. Hence, the AR-regulated AIFM2, APAF1, and BCL2 family genes are putative AR 
targets. Importantly, future experiments designed to examine the transcriptional rates of these 
genes, the stability of their transcripts, and AR occupancy at these genes are needed to 
demonstrate AR-mediated transcriptional regulation of these genes. 
 
Conclusions 
In conclusion, we report that AR exerts pro-apoptotic function in HPr-1AR and RWPE-
AR human prostate epithelial cells. Although androgen alone does not induce cell death, it 
sensitizes HPr-1AR and RWPE-AR to cell stress agents that induce apoptosis. We also found 
that the pro-apoptotic function of AR requires transcription. We further propose that AR-
mediated transcriptional activation of pro-apoptotic genes (including BCL2L11/BIM and 
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AIFM2) and transcriptional repression of pro-survival genes (including BCL2L1/BCL-XL and 
MCL1) lowers the threshold necessary to achieve mitochondrial outer membrane 
permeabilization, thus rendering HPr-1AR more vulnerable to cell stress and death signals. 
Taken together, our study offers insights into the apoptotic function and mechanism of AR 
signaling in the androgen-responsive gene network of prostate epithelial cells. Future studies are 
needed to investigate whether pro-apoptotic signaling by AR is common in other cellular 
contexts and in vivo. 
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Table 3.1. Primers for QPCR amplicons. 
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Table 3.2. ANOVA data from live cell populations quantified by flow cytometry. 
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Figures 
 
Fig. 3.1. Androgen and staurosporine synergize to decrease the relative ATP concentration in HPr-
1AR cells.  
(A) HPr-1AR cells were treated with a range of DHT concentrations or vehicle control for 18 hours and 
then co-treated with 1 µM STS or vehicle control for 6 hours. Relative ATP concentrations available for 
biochemical processes in metabolically active cells were quantified using a luciferase-based bioassay for 
relative ATP levels in cultured cells. In comparison to vehicle control, STS and to a lesser extent DHT 
significantly decrease the relative ATP concentration of HPr-1AR cells at 24 hours. In addition, ANOVA 
revealed significant interaction between 1 µM STS and 0.1-10 nM DHT, which is visually evident from 
the unparallel trends of the white bars and black bars in the plot. Estimates of the interaction effect and 
corresponding p-values are indicated. Negative interaction terms indicate synergy whereas positive values 
indicate antagonism between DHT and STS. (B) Cells were treated with 10 nM DHT or vehicle control 
for 24 hours and then co-treated with 0.5 µM STS for 0, 3, 6, or 9 hours (h). In comparison to control-
treated HPr-1AR cells (circles), DHT-treated HPr-1AR cells (squares) had 40%, 72%, and 76% 
reductions in ATP levels after 3, 6, and 9 hours of STS co-treatment, respectively. For time course 
analysis, significance differences between androgen treatment and vehicle control were determined at 
each time point using Student’s t-test and adjusted using the Bonferroni method, * P < 0.05. (C) Cells 
were treated with 1 nM DHT or vehicle control in the absence or presence of 5 µM enzalutamide (ENZ) 
for 18 hours and then co-treated with 1 µM STS or vehicle control for 6 hours. AR antagonist, ENZ 
significantly suppresses the synergistic interaction between DHT and STS. (D) Cells were treated with 5 
μM PD0332991, a selective inhibitor of CDK4/6 kinase activity, for 18 hours to mimic the inhibitory 
effect of DHT on HPr-1AR cell cycle progression and growth, and then these cells were co-treated with 1 
µM STS or vehicle control for 6 hours. The positive interaction term indicates that the synergy between 
DHT and STS on ATP depletion is not dependent on growth suppression and suggests an antagonistic 
effect between STS and PD0332991. Data represent the mean ± SEM (n ≥ 4). 
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Fig. 3.2. Androgen sensitizes HPr-1AR and RWPE-AR to apoptotic cell death. 
(A) HPr-1AR cells were treated with 1 nM DHT or vehicle control in the absence or presence of 5 µM 
ENZ for 19 hours and then co-treated with 1 µM STS or vehicle control for 5 hours. Cells were harvested, 
stained with annexin V and PI, and the fluorescence intensities of annexin V and PI stained cells were 
quantified by flow cytometry. Viable live cells (annexin V-negative and PI-negative, gray dots), early 
apoptotic cells (annexin V-positive and PI-negative, blue dots), and late apoptotic cells (annexin V-
positive and PI-positive, orange dots) are indicated. (B) Quantification of the fraction of viable live (gray 
bar with black number), early apoptotic (blue bar with white number), and late apoptotic cells (orange bar 
with gray number) is shown from the dot plots in Fig. 3.2A. DHT treatment alone does not trigger cell 
death in HPr-1AR. However, DHT sensitizes HPr-1AR to STS-induced apoptosis. In addition, AR  
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Fig. 3.2 (cont.) 
antagonist, ENZ, suppresses the synergistic interaction between DHT and STS, which significantly 
increases the live cell proportion. (C) HPr-1AR cells were treated with 1 nM DHT or vehicle control for 
12 hours and then co-treated with apoptosis inducer, TNFα+CHX, or vehicle control for 11 hours. The 
fluorescence intensities of annexin V and PI stained cells were then quantified by flow cytometry. DHT 
sensitizes HPr-1AR cells to apoptotic death induced by TNFα+CHX. (D) HPr-1AR cells were treated 
with 1 nM DHT or vehicle control for 20 hours and then co-treated with apoptosis inducer, H2O2, or 
vehicle control for 24 hours. The fluorescence intensities of annexin V and PI stained cells were then 
quantified by flow cytometry. DHT sensitizes HPr-1AR cells to apoptotic death induced by H2O2. (E) 
RWPE-AR cells were treated with 1 nM DHT or vehicle control in the absence or presence of 5 µM ENZ 
for 30 hours and then co-treated with 1 µM STS or vehicle control for 10 hours. The fluorescence 
intensities of annexin V and PI stained cells were then quantified by flow cytometry. DHT treatment 
alone does not induce cell death in RWPE-AR. However, DHT sensitizes RWPE-AR to STS-induced 
apoptosis. Further, ENZ co-treatment completely suppresses the synergistic interaction between DHT and 
STS, fully rescuing the live cell proportion of RWPE-AR. Data represent the mean (n ≥ 3). Comparisons 
between multiple treatment groups were performed using three- or two-way ANOVA followed by 
Tukey's honest significant difference test (Table 3.2). 
  
98 
 
 
Fig. 3.3. Androgen-sensitized apoptosis of HPr-1AR cells involves caspase activation. 
(A) HPr-1AR cells were treated with 10 nM DHT or vehicle control for 18 hours and co-treated with 1 
µM STS for 0 to 10 hours. Immunoblot analysis was performed using antibodies that detect the cleaved 
and active forms of caspase-9 (35 kDa) and caspase-3 (19 and 17 kDa). HPr-1AR cells pretreated with 
DHT show rapid activation of caspase-9 and caspase-3 upon STS co-treatment, whereas DHT or STS  
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Fig. 3.3 (cont.) 
treatment alone show little or no caspase activation. (B) Cells were treated with 1 nM DHT or vehicle 
control in the absence or presence of 5-10 µM ENZ for 18 hours and then co-treated with 1 µM STS or 
vehicle control for 6 hours. The DHT-induced cleavage of caspase-9 and caspase-3 in STS-treated HPr-
1AR cells is completely suppressed by AR antagonist, ENZ. (C) Cells were treated with 1-10 nM DHT or 
vehicle control for 18 hours and then co-treated with TNFα+CHX or vehicle control for 10 hours. 
Immunoblot analysis was performed using an additional antibody to detect the cleaved and active form of 
caspase-8 (18 kDa), an initiator caspase that is activated in response to extrinsic apoptotic stimuli, such as 
TNFα. DHT and TNFα+CHX synergistically enhance cleavage of caspase-9 and caspase-3, whereas DHT 
or TNFα+CHX treatment alone shows no significant activation of caspase-9 or caspase-3. The arrows and 
corresponding molecular weights indicate the different caspase forms. (D) HPr-1AR cells were treated 
with 1 nM DHT or vehicle control for 24 hours and co-treated with 200 µM H2O2 for 0 to 10 hours. HPr-
1AR cells pretreated with DHT show rapid activation of caspase-3 upon H2O2 co-treatment, whereas 
DHT or H2O2 alone show little or no caspase-3 activation. (E) RWPE-AR cells were treated with 1 nM 
DHT or vehicle control for 38 hours and then co-treated with 1 µM STS or vehicle control for 5 to 10 
hours. RWPE-AR cells pretreated with DHT show rapid and robust activation of caspase-3 upon STS co-
treatment (11-fold at 5 hours and 23-fold at 10 hours) compared to RWPE-AR cells pretreated with 
vehicle as a control. Immunoblot results were quantified and represented as the mean ± SEM (n ≥ 3). 
Comparisons between different treatments were performed using two-way ANOVA followed by Tukey's 
honest significant difference test. 
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Fig. 3.4. Androgen and staurosporine synergize to induce mitochondrial depolarization in HPr-
1AR.  
(A-E) HPr-1AR cells were treated with 10 nM DHT or vehicle control for 20 hours and then co-treated 
with 2 µM STS or vehicle control for 4.5 hours. Cells treated with vehicle control were used as the 
negative control. In addition, 2 µM CCCP was added to an aliquot of the negative control cells to 
depolarize their mitochondria and generate the positive control. Cells were stained with JC-1 dye and 
analyzed using flow cytometry. For each treatment, the ratios of red to green fluorescent intensities are 
displayed in histograms. Blue brackets at the left of each panel specify the population of cells with 
depolarized mitochondria. Normal cells (A) have a wide and bell-shaped distribution of JC-1 stained 
mitochondria, whereas cells with depolarized mitochondria have a sharp and left-shifted distribution (B). 
(F) Quantification of the depolarized cell proportion for each treatment revealed that DHT or STS alone 
do not significantly increase mitochondrial depolarization. However, co-treatment with DHT and STS 
significantly increases the depolarized population by 4-fold or more. Data represent the mean ± SEM (n = 
4). Comparisons between different treatments were performed using two-way ANOVA followed by 
Tukey’s honest significant difference test. 
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Fig. 3.5. Transcription and protein synthesis are necessary for androgen-sensitized apoptosis of 
HPr-1AR.  
(A) Cells were treated with 1 nM DHT or vehicle control in the absence or presence of transcription 
inhibitor, 20 μg/mL 5,6-dichlororibofuranosylbenzimidazole (DRB), for 16 hours, and then these cells 
were co-treated with 1 µM STS or vehicle control for 4 hours to induce apoptosis. Cells were harvested, 
stained with annexin V and PI, and the intensities of annexin V and PI stained cells were quantified by 
flow cytometry. DRB treatment significantly suppressed the androgen-sensitized apoptosis of HPr-1AR. 
(B) HPr-1AR cells were treated with 1 nM DHT or vehicle control in the absence or presence of protein 
synthesis inhibitor, 25 μg/mL CHX, for 16 hours, and then these cells were co-treated with 1 µM STS or 
vehicle control for 4 hours to induce apoptosis. Cells were harvested, stained with annexin V and PI, and 
analyzed by flow cytometry. CHX co-treatment completely suppressed the androgen-sensitized apoptosis 
of HPr-1AR. Data represent the mean (n = 3). Comparisons between multiple treatment groups were 
performed using three-way ANOVA followed by Tukey's honest significant difference test (Table 3.2). 
(C) Immunoblot analysis of cell lysates reveals that DHT-induced caspase-3 cleavage in STS-treated HPr-
1AR cells is significantly suppressed by the inhibition of transcription (DRB) and protein synthesis 
(CHX). 
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Fig. 3.6. AR-mediated transcriptional regulation of apoptotic genes in HPr-1AR. 
(A) Cells were treated with 10 nM DHT or vehicle control for 24 hours. Total RNA was isolated, cDNA 
was synthesized by reverse transcription, and the relative mRNA levels of apoptosis-related genes were 
quantified by QPCR analysis. The colorimetric representation shows genes, indicated by HUGO Gene 
Nomenclature Committee gene symbols, whose transcripts were induced (red), unresponsive (black), and 
repressed (green) by androgen. The color intensity reflects the relative fold change (brightest red = 4-fold 
increase and brightest green = 4-fold decrease) in transcript level for DHT- versus vehicle control (CTL)-
treated cells (n = 3). The 2-fold cutoff boundaries (orange lines) and 1.5-fold cutoff boundaries (gray 
lines) were determined from the mean change in expression level for DHT- versus CTL-treated cells. (B) 
Cells were treated with 1 nM DHT or vehicle control in the absence or presence of 5 µM ENZ for 24 
hours. QPCR analysis demonstrates that the pro-apoptotic genes (BCL2L11 and AIFM2) are DHT-
induced, whereas the pro-survival genes (BCL2L1 and MCL1) are DHT-repressed. Further, the AR 
antagonist, ENZ, completely suppressed the androgen-responsive mRNA changes. Data represent the 
mean ± SEM (n = 3) in log2 scale. Comparisons between different treatments were performed using two-
way ANOVA followed by Tukey’s honest significant difference test. (C) HPr-1AR cells were treated 
with 10 nM DHT for 24 hours. Immunoblot analysis of BCL2 family gene products demonstrates that the 
expression of pro-apoptotic BCL2L11/BIM is androgen-induced, whereas pro-survival proteins, 
BCL2L1/BCL-XL and MCL1, are androgen-repressed. Representative immunoblots (left panel) and the 
quantified results (right panels) are shown. Data represent the mean ± SEM (n = 4). Comparisons between 
DHT- versus vehicle-treated cells were made using Student’s t-test, * P < 0.05. 
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Fig. 3.7. A model for androgen-sensitized apoptosis of HPr-1AR. 
Activation of AR by agonists, such as DHT, enhances AR nuclear accumulation and transcriptional 
regulation of target genes, including genes involved in the regulation of apoptosis. We propose that AR 
exerts pro-apoptotic roles by modestly up-regulating the expression of pro-apoptotic genes 
(BCL2L11/BIM and AIFM2) and down-regulating the expressions of pro-survival genes (BCL2L1/BCL-
XL and MCL1). The modest changes in the expression of the BCL2 family proteins may explain why 
DHT treatment alone does not induce apoptosis in HPr-1AR cells. However, the multi-target regulation of 
BCL2 family proteins by AR signaling may sufficiently stress the mitochondria towards a pro-apoptotic 
state (i.e., leaky outer membrane) and decrease the threshold for other apoptotic stimuli to further enhance 
permeabilization of the mitochondrial outer membrane above the necessary threshold for initiator and 
executioner caspase activation (caspase-9 and caspase-3, respectively) and apoptotic disassembly of the 
cells. 
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Fig. 3.8. AR protein expression in HPr-1AR and RWPE-AR cell lines. 
Immunoblots show robust AR protein expression in HPr-1AR and RWPE-AR lysates compared to HPr-1 
and RWPE-FG9 lysates. AR protein expression is nearly 3-fold higher in HPr-1AR compared to RWPE-
AR. 
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Fig. 3.9. AR antagonist, 2-hydroxyflutamide, suppresses synergy between androgen and 
staurosporine to rescue HPr-1AR cell viability. 
Cells were treated with 1 nM DHT or vehicle control and 10 µM 2-hydroxyflutamide (OHF) for 18 hours 
and then co-treated with 1 µM STS or vehicle control for 6 hours. AR antagonist, OHF, significantly 
suppresses the synergistic interaction between DHT and STS. Data represent the mean ± SEM (n = 4). 
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Fig. 3.10. Absence of synergy between androgen and staurosporine in HPr-1 and RWPE-FG9 cell 
lines, which lack AR protein expression. 
(A) HPr-1 cells were treated with 1 nM DHT or vehicle control 21 hours and then co-treated with 0.5-1 
µM STS or vehicle control for 4 hours. Cells were harvested, stained with annexin V and PI, and the 
fluorescence intensities of annexin V and PI stained cells were quantified by flow cytometry. 
Quantification of the fraction of viable live (gray bar with black number), early apoptotic (blue bar with 
white number), and late apoptotic cells (orange bar with gray number) is shown. DHT treatment alone 
does not trigger cell death in HPr-1. Further, DHT does not sensitize HPr-1 to STS-induced apoptosis. (B) 
RWPE-FG9 cells were treated with 1-10 nM DHT or vehicle control for 29 hours and then co-treated 
with 1 µM STS or vehicle control for 10 hours. The fluorescence intensities of annexin V and PI stained 
cells were then quantified by flow cytometry. DHT treatment alone does not induce cell death in RWPE-
FG9. Further, DHT does not sensitize RWPE-FG9 to STS-induced apoptosis. Data represent the mean (n 
= 3). Comparisons between multiple treatment groups were performed using two-way ANOVA followed 
by Tukey's honest significant difference test (Table 3.2). 
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Chapter 4 
Discussion 
Androgen receptor (AR) signaling plays crucial roles in the regulations of prostate 
development, maturation, and homeostasis and pathogenesis. At the cellular and tissue level, an 
important aspect of homeostasis is the regulation of cell number, which is dependent upon the 
balance between cell division and cell death. While the proliferative actions of androgen-
activated AR have been extensively investigated in prostate cancer cells, the AR-mediated 
signaling in normal/benign adult prostate epithelium is not well understood. Several recent 
studies using in vitro and in vivo model systems have revealed that AR signaling drives 
differentiation rather than proliferation in adult prostate epithelium under physiologic conditions; 
however, the mechanism underlying this is unclear [120,158,165]. In comparison to AR-
mediated cell growth and proliferation, AR-mediated cell death has remained unexplored, 
although the knowledge gained from its elucidation is expected to offer insights into prostate 
homeostasis and key signaling events that become dysregulated in prostate neoplasia. In this 
dissertation, we have explored these unknowns and investigated the mechanisms involved in 
AR-mediated growth suppression and cell death of human prostate epithelial cell lines. 
In Chapter 2, we interrogated the functional role of AR signaling in the growth and 
division of prostate epithelial cell lines, HPr-1AR and PC3-Lenti-AR. Using these in vitro cell 
culture systems, we confirmed that AR signaling suppresses the growth of HPr-1AR cells by 
arresting the cell cycle in G0/G1 phase. Cyclin D-CDK complexes, which are key regulators of 
the G1/S-phase transition, are targeted and inhibited by AR signaling (Fig. 4.1). Gene expression 
analyses indicated that DHT treatment inhibits the activity of cyclin D-CDK complexes by AR-
mediated repression of CDK4/6 and cyclin D1/2 transcription and induction of CDKN1A/p21 
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transcription. Overexpression of each of these components validated their roles in androgen-
induced growth suppression. Similar growth suppression and gene regulation patterns were also 
observed in PC3-Lenti-AR (Fig. 2.7) and RWPE-AR cells (Chen and Bolton, unpublished data), 
indicating the AR-mediated transcriptional regulation of cell cycle-related genes is likely a 
general mechanism responsible for androgen-induced growth suppression of non-malignant 
human prostate epithelial cells.  
In Chapter 3, we investigated the role of AR-mediated signaling in the apoptotic stress 
response of prostate epithelial cell lines, HPr-1AR and RWPE-AR. Although DHT treatment by 
itself does not induce cell death, DHT co-treatment sensitizes HPr-1AR cells to apoptosis in 
response to a wide-range of cell stress agents. The AR-mediated sensitization to cell stress was 
achieved by the regulation of mitochondrial membrane permeability (Fig. 4.1). Gene expression 
analyses revealed that DHT induces pro-apoptotic BCL2 family genes, BIM and BOK, and 
represses pro-survival BCL2 family genes, BCL-XL and MCL1. Overall, the changes in the 
expression of theses BCL2 family genes are consistent with a decrease in the threshold for 
mitochondrial outer membrane permeabilization (MOMP), thus rendering HPr-1AR cells more 
vulnerable to apoptotic stress signals. In addition, the AR-sensitized cell death was also detected 
in RWPE-AR (Fig. 3.2) and PC3-Lenti-AR (Chen and Bolton, unpublished data). Therefore, 
AR-mediated cell death seems to be a common response to cell stress agents in human prostate 
epithelial cells. 
 
 
 
109 
Crosstalk between AR-mediated Anti-proliferative and Pro-apoptotic Signaling 
Pathways 
We have summarized that AR exerts anti-proliferative and pro-apoptotic functions 
through the regulation of cell cycle-related genes and BCL2 family genes, respectively. It is 
intriguing to ask whether the two pathways are intertwined. Specifically, whether the regulation 
of cell cycle-related genes contributes to the regulation of cell death, or vice versa. For the 
former question, several studies have suggested that cyclins, CDKs, and CDK inhibitors are 
indeed involved in the regulation of apoptosis. The activation of cyclins and CDKs is positively 
correlated with the onset of apoptosis [240,241,243,264]. Overexpression of cyclin D1, cyclin A, 
and CDK1-4 have been shown to either induce apoptosis, or sensitize cells to STS- or TNFα-
induced apoptosis in the context of different cell culture systems [240,241,243]. Accordingly, 
inhibition of CDK activity by overexpression of dominant negative variants or CDK inhibitors 
has been shown to protect cells against apoptosis [240]. To date, the exact role of CDKs in 
apoptosis regulation is not well defined. However, the pro-apoptotic BCL2 family gene, BAD, 
was found to be a substrate of CDK1 that is activated by CDK1 phosphorylation [264]. In 
addition, the cell cycle inhibitor, CDKN1A/p21, has been suggested to provide protection against 
apoptosis in different cellular contexts [242,244,245,265,266]. CDKN1A/p21 has been suggested 
to directly interact with pro-caspase-3 and prevent its activation [267,268]. Overexpression of 
CDKN1A/p21 reportedly represses the expression of caspase-2, an upstream apoptotic regulator 
of MOMP [269].  In addition, CDKN1A/p21 may indirectly suppress caspase activation by 
inhibition of CDK activity [270]. Collectively, these findings indicate that proliferating cells are 
more susceptible to apoptosis in comparison to quiescent cells. Therefore, the DHT-repressed 
expressions of cyclin D1/2 and CDK4/6, and the DHT-induced expression of CDKN1A/p21 that 
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we described in Chapter 2 are not central to the mechanism of DHT-sensitized apoptosis 
described in Chapter 3. Rather, the AR-mediated transcriptional changes involved in growth 
suppression may serve to protect prostate epithelial cells against stress and apoptosis. 
In addition, several recent studies have suggested the involvement of apoptosis-related 
genes in the cell cycle regulation. Intriguingly, CDKN1A/p21 is an early target of caspase-3. The 
truncation and inactivation of CDKN1A/p21 and the subsequent activation of CDK2 are 
potential facilitators of apoptosis execution [271]. Upon MOMP and caspase-3 activation, cells 
are committed to irreversible apoptotic cell death [272]. Therefore, the inactivation of pro-
survival CDKN1A/p21 may be part of a feedback loop, which potentiates apoptosis. Of note, the 
BCL2 family genes have also been implicated in the regulation of cell cycle progression 
[273,274].  Overexpression of pro-survival BCL2 or BCL-XL delays exiting the G0-phase 
entering the cell cycle, possibly through the induction of CDKN1B/p27 and p130 [275,276], 
whereas overexpression of pro-apoptotic BAX accelerates the G1/S-phase transition [277]. In 
addition, the transcription of pro-apoptotic BOK remains low in quiescent cells and rises during 
G1/S-phase progression, suggesting a positive role of BOK in cell cycle progression [278]. It is 
somewhat paradoxical that the pro-survival BCL2 family genes, which inhibit apoptosis, also 
suppress cell growth and proliferation. A plausible but not tested interpretation is that the pro-
survival BCL2 family genes may have evolved as part of a growth suppression mechanism to 
restrain cell proliferation. Whether the pro-survival or anti-proliferative function is dominant 
may be dependent on cellular context. In HPr-1AR cells, DHT treatment arrests cell cycle in 
G0/G1 phase at 24 hours primarily through the repression of cyclin D-CDK complexes.  
Interestingly, the AR-mediated cell cycle inhibition of HPr-1AR attenuates after several days. 
One possible mechanism based on the discussion above is that AR-mediated expression changes 
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in BCL2 family proteins, including DHT-repressed BCL-XL and DHT-induced BOK, may 
relieve the cell cycle inhibition in addition to their roles as apoptosis regulators. However, this 
hypothesis remains untested. 
In summary, mounting evidence indicates that the functions of cell cycle-related genes 
and apoptosis-related genes are not only limited to the regulation of cell division and cell death, 
respectively. Rather, the cell cycle and apoptosis pathways are likely interconnected. In HPr-
1AR cells, the AR-mediated expression pattern of cell cycle-related genes and apoptosis-related 
genes tends to weaken the biological outcome of the other, which is consistent with a reciprocal, 
negative feedback mechanism to prevent excessive growth inhibition or cell death. Future 
experiments using prostate epithelial cell lines, in which cell cycle-related or apoptosis-related 
gene products have been stably overexpressed or depleted, shall provide more insights into the 
regulatory crosstalk between AR-mediated cell cycle progression and apoptotic cell death. 
 
Integration of Cell Cycle, Autophagy, and Apoptosis Pathways in an AR-mediated 
Signaling Network 
In the previous chapters, we described the anti-proliferative and pro-apoptotic functions 
of AR signaling in prostate epithelial cells and proposed distinct mechanisms whereby AR 
regulates the expressions of cyclin-CDK complex genes and BCL2 family genes, respectively. 
Although the validation of gene function experiments from our laboratory and other groups have 
shown that expression changes for these gene products are sufficient to inhibit cell cycle or 
facilitate mitochondrial apoptosis, we cannot exclude the possibility that other AR-regulated 
genes also contribute to the regulation of cell cycle arrest and apoptosis. In support of this, we 
have observed that DHT-treated HPr-1AR cells tend to accumulate more vacuole-like structures 
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in their cytoplasm compared to vehicle-treated cells (Chen and Bolton, unpublished data). 
Additional gene expression analyses have revealed that several autophagy-related genes (ATGs) 
are transcriptionally induced by AR signaling (Chen and Bolton, unpublished data). These 
preliminary results raise the possibility that AR also functions as an autophagy mediator in 
prostate epithelial cells. Consistent with our speculation, recent studies have suggested signaling 
pathways that regulate cell cycle progression/arrest, autophagy, and apoptosis may intersect 
forming a complex signaling network [273,274,279-281]. Thus, the AR-mediated regulation of 
the ATGs may also contribute to the anti-proliferative and pro-apoptotic functions of AR 
signaling. We discuss these possibilities herein. 
Autophagy, which literally means “self-eating”, is an evolutionarily conserved 
physiologic phenomenon that functions to maintain cellular homeostasis through protein 
degradation and organelle turnover [83]. A hallmark of autophagy is the formation of a double-
membrane autophagosome, which eventually fuses with a lysosome to deliver its contents for 
degradation (Fig. 4.2) [279]. Upon nutrient deprivation, macroautophagy (or simply 
“autophagy”) serves to degrade regions of cytoplasm in an attempt to acquire sources of 
metabolic energy and requisite materials [279]. The process of macroautophagy is thought to 
proceed stepwise with each step being mediated by multimeric ATG complexes (Fig. 4.2). The 
unc-51 like autophagy activating kinase 1/2 (ULK1/2) – autophagy related 13 (ATG13) - RB1 
inducible coiled-coil 1 (RB1CC1) preinitiation complex, is activated upon nutrient deprivation 
and therefore activates the Class III phosphatidylinositol 3-kinase (PI3K) initiation complex 
through the phosphorylation of key components including Beclin-1/ATG6 [282-286]. BCL2 
family proteins, including BCL2 and BCL-XL, have been shown to interact with Beclin-1 and 
disrupt the initiation of autophagy [287]. Activation of the Class III PI3K initiation complex is 
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thought to increase the concentration of phosphatidylinositol 3-phosphate (PI3P) at the 
nucleation site of the isolation membrane. PI3P has been implicated in recruitment of elongation 
machinery as well as formation and closure of the autophagosome [288]. During the elongation 
reaction, the key autophagosome marker, LC3-II, is generated and conjugated to the 
autophagosome membrane by a process resembling ubiquitination [289]. First, LC3-I is 
generated by a protease, ATG4, which cleaves LC3 to LC3-I [290-292]. Next, LC3-I is bound by 
ATG7 (an E1-like activating enzyme) and transferred to ATG3 (an E2-like conjugating enzyme) 
[293]. Later, LC3-I is conjugated to phosphatidylethanolamine (LC3-PE or LC3-II) by the 
ATG12-ATG5-ATG16L1 complex (an E3-like ligase) [294]. The LC3 lipidation process is 
required for the formation of autophagosomes, and LC3-II remains stably associated with mature 
autophagosomes. The mature autophagosomes eventually fuse with lysosomes, allowing for 
degradation and recycling of their contents. Besides starvation-induced macroautophagy, 
additional selective autophagy mechanisms that target damaged or unwanted organelles to 
lysosomes for turnover have been described [295-299]. The best-studied type of selective 
autophagy is mitophagy, which selectively removes damaged mitochondria and therefore plays a 
crucial role in cellular homeostasis and survival. 
Our preliminary data suggests that DHT treatment induces the expression of autophagy-
related genes, ULK1, ATG12 and ATG4B (Chen and Bolton, unpublished data). Interestingly, 
ULK1 is a serine/threonine kinase and core signaling component of the Class III PI3K 
preinitiation complex, whereas ATG12 and ATG4B are involved in LC3-II processing and 
elongation of the isolation membrane (Fig. 4.2). The AR-mediated up-regulation of these genes 
suggests that AR signaling may stimulate autophagy in HPr-1AR cells. As AR signaling 
modulates the stress response of HPr-1AR prostate epithelial cells via MOMP, we further 
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propose that the AR-regulated expressions of ATGs may mediate selective autophagy, 
specifically mitophagy. Consistent with this hypothesis, DHT treatment alone slightly decreased 
the proportion of depolarized mitochondria in mitochondrial potential experiments (Fig. 3.4). 
Although this difference was not detected by ANOVA (possibly due to a weak effect and small 
sample size), there was a subtle but consistent trend, implying androgen action may influence 
mitochondrial potential. Similarly, when HPr-1AR cells were treated with a low dose of AT101 
(1 μM), which is a BCL2/MCL1-selective antagonist, physiologic doses of DHT (1-10 nM) 
suppressed the decrease of intracellular ATP concentration in response to AT101 by 
approximately 5% (Chen and Bolton, unpublished data). Although a larger sample size is 
required to detect such a subtle effect statistically, these results nonetheless hint that AR 
signaling may initially activate mitophagy signaling in an attempt to save the cell before the 
cellular stress response crosses the threshold for MOMP-induced apoptosis. Such a protective 
effect seems to contradict to the outcome of AR-induced pro-apoptotic factors (BIM, AIFM2 and 
BOK) and AR-repressed pro-survival factors (BCL-XL and MCL1), and therefore is likely 
mediated by a different pathway. It is intriguing to speculate that the addition of mitophagy 
signaling into our model may offer a reasonable explanation. As the cellular stress response is 
being activated and the AR-regulated BCL2 family genes sensitize HPr-1AR cells to MOMP-
induced apoptosis, AR-regulated mitophagy may also attempt to clear the damaged mitochondria 
and therefore promote cell survival. Future experiments, which examine autophagy flux and 
mitochondrial status in response to androgen and cell stress agents, are needed to elucidate the 
role of AR signaling in autophagy/mitophagy of prostate epithelial cells. 
Another curious aspect of the AR-induced ATGs is their reported involvement in the 
regulation of cell cycle progression/arrest and apoptosis. In addition to their autophagy-related 
115 
functions, ULK1 has been shown to inhibit cell proliferation and ATG12 has been shown to 
induce apoptosis. Overexpression and knockdown experiments of ULK1 in model organisms and 
mammalian cells have demonstrated that ULK1 mediates phosphorylation and inhibition of 
TOR/S6K signaling, thus making it a negative regulator of cell growth and proliferation (Fig. 
4.2) [300,301]. Notably, ULK1-mediated growth suppression is not dependent on the autophagy 
process [300]. ATG12, like ULK1, has recently been investigated for functions beyond 
autophagy. In addition to serving as a key component of the isolation membrane elongation 
complex (ATG12-ATG5-ATG16L1 complex), ATG12 is also a mediator of mitochondrial 
homeostasis and apoptosis [302,303].  Disruption of the ATG12-ATG3 covalent conjugate 
complex hinders the clearance of damaged mitochondria and suppresses intrinsic, mitochondrial 
apoptosis [302] (Fig. 4.2). Further, the free form of ATG12 has been shown to bind to and 
inactivate the pro-survival factors, BCL2 and MCL1, through its BH3-like domain, leading to 
BAX activation and mitochondrial apoptosis (Fig. 4.2) [303]. Based on these reports, we propose 
that the AR-induced expressions of ULK1 and ATG12 may also contribute to anti-proliferative 
and pro-apoptotic functions of AR signaling in human prostate epithelial cells. Future studies to 
evaluate cell proliferation and stress response in prostate epithelial cell lines that either 
overexpress or are deficient for ULK1 and ATG12 are needed to elucidate the function of these 
genes in the regulation of cell cycle and death. 
 
Functional Roles of AR Signaling in Prostate Epithelial Cell Homeostasis 
The integration of our studies has begun to reveal a homeostatic model for the AR-
mediated regulation of cell number using HPr-1AR and other human prostate epithelial cell lines 
in culture. We have concluded that 1) AR signaling directly suppresses epithelial cell 
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growth/division under optimal culture conditions and 2) AR signaling sensitizes epithelial cell to 
apoptosis and facilitates damaged cell removal under stressed conditions (Fig. 4.1). However, the 
physiologic relevance of studies performed using cell lines in culture must be considered. Here, 
we compare our results with other published data and evaluate several of our conclusions in the 
context of other in vitro and in vivo systems. 
The parental HPr-1AR cell line, HPr-1, originated from the immortalization of an AR-
negative prostate basal epithelial cell and therefore differs from well-differentiated prostate 
luminal epithelial cells. Stable overexpression of AR in parental HPr-1 cells led to androgen 
sensitivity of these non-malignant cells, and androgen-induced expression of luminal cell 
markers (e.g. PSA, CK8 and CK18). Hence, HPr-1AR cells behave more like intermediate cells 
of the prostatic epithelium, which differentiate into luminal epithelial cells in the presence of 
androgen. The anti-proliferative function of AR that we described in HPr-1AR cells indicates 
that AR signaling reduces the proliferative potential of progenitor/intermediate cells and may 
drive the differentiation of luminal epithelial cells. In addition to our study, the anti-proliferative 
effects of AR signaling have been described in benign prostate epithelial cell lines of humans 
and rodents. The luminal cells in benign prostatic epithelium are quiescent and well-
differentiated, so they do not proliferate. Therefore, non-malignant prostate epithelial cell lines 
are typically derived from the basal epithelial layer, where AR-negative basal or progenitor cells 
reside. Several groups have shown that the expression of AR in prostate epithelial cells of the 
basal layer exerts growth suppressive effects and may enhance androgen-induced differentiation 
of luminal epithelial cells [120,158,165]. Ling et al. developed HPr-1AR cell line and first 
described that mibolerone (a synthesized androgen) treatment retards cell growth, induces 
cytodifferentiation morphology and the expression of proteins commonly used as luminal 
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epithelial markers (e.g. CK8, CK18, PSA, CDKN1A) [165]. Similarly, AR activation in rat basal 
epithelial cell line CA25 leads to growth inhibition and a columnar epithelial cell-like 
morphology [158]. In addition, Lee et al. showed AR expression suppresses self-
renewal/proliferation of both human prostate basal epithelial cell line (HPrE) and mouse 
basal/progenitor epithelial cell line (mPrE). In HPrE cells, DHT increases transcription of 
luminal cell markers, including PSA, CK8 and NKX3.1, and decreases expression of CK5, a 
basal cell marker [120]. The same AR-regulation of CK8 and CK5 was also observed in mPrE 
cells [120]. Collectively, these findings indicate that AR signaling suppresses the growth and 
proliferation of benign adult prostate epithelial cells in culture.  
In comparison to the anti-proliferative function of AR, the pro-apoptotic function of AR 
signaling in the cellular stress response is not well-documented. Cell survival/death has been 
investigated in both HPr-1AR and AR-positive CA25 cell lines under optimal culture conditions, 
and no significant apoptosis was detected with androgen by itself compared to vehicle as a 
control [158,165,222]. Therefore, AR activation is not sufficient to induce apoptosis in these 
cells, which is consistent with the role of AR signaling in vivo in luminal epithelial cells, which 
robustly express AR [119,120]. However, when androgen-induced human prostate epithelial 
cells are exposed to cell stress agents, our results indicate that AR signaling potentiates pro-
apoptotic signaling human prostate epithelial cell lines (HPr-1AR and RWPE-AR). The pro-
apoptotic function of AR that we described indicates AR signaling limits cell survival upon 
activation of the cellular stress response in the precursors of luminal epithelial cells. As such, 
pro-apoptotic AR signaling may serve to remove damaged cells from the prostatic epithelium, 
rather than allow these compromised cells to survive. In addition, our preliminary data indicate 
that AR activation sensitizes the prostate cancer cell line, PC3-Lenti-AR, to STS-induced cell 
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death (Chen and Bolton, unpublished data). Consistent with these findings, Xiang et al. have 
shown that AR expression in another prostate cancer cell line, LNCaP-104-R1, sensitizes these 
cells to ultraviolet or STS-induced apoptosis [238,239,246]. Although the mechanisms whereby 
AR mediates pro-apoptotic function may differ among the non-malignant and malignant prostate 
cell lines, these findings nonetheless suggest that the pro-apoptotic function of AR signaling may 
be a common determinant of prostate epithelial cell survival/death. 
Importantly, the anti-proliferative function of AR signaling in vivo has also been shown 
using tissue-specific AR knockout (ARKO) mice. Wu et al. generated knockout mice that lack 
epithelial AR within the mature prostate and observed hyperproliferative and less differentiated 
prostate tissue in these mice, evidenced by increased BrdU-positive epithelial cells and decreased 
epithelial height, glandular infolding and differentiation markers [119]. In a follow-up study, Lee 
et al. generated basal epithelium-specific ARKO mice and concluded that AR plays a negative 
role in CK5-positive basal epithelial or progenitor (intermediate) cell proliferation [120]. 
Therefore, the anti-proliferative function of AR signaling in epithelial cell lines derived from the 
basal layer is consistent with ARKO studies in vivo. The authors excluded the involvement of 
apoptosis in the regulation of cell number in the epithelial layers of ARKO mice [119,120]. In 
the prostate lumen of epithelial ARKO mice, more dead cells and DNA fragmentation were 
reported. The authors further suggested that such cell death is more likely mediated through 
anoikis rather than apoptosis due to the detachment of the cells from their basement membrane 
[119].  Unfortunately, the pro-apoptotic function of AR signaling in response to cellular stress 
in vivo was not tested in these studies. Hence, whether AR signaling enhances the clearance of 
damaged epithelial cells in vivo remains unclear. In addition, paracrine-mediated regulation of 
prostatic epithelial proliferation by the AR in the prostatic stroma has also been explored. ARKO 
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in stromal smooth muscle and/or stromal fibroblast cells led to decreased epithelial proliferation, 
loss of infolding glandular structures and increased cell death [121,304,305].  The epithelial 
defects were partially rescued by adding exogenous growth factors [121].  Taken together, the 
studies utilizing tissue-specific ARKO mice are consistent with AR-mediated regulation of 
epithelial cell proliferation and survival/death. The epithelial AR directly suppresses the growth 
and division of epithelial cells, whereas the stromal AR indirectly promotes the proliferation and 
survival of these cells by secretion of paracrine growth factors.  
In conclusion, the anti-proliferative function of AR signaling we described in HPr-1AR is 
concordant with other in vitro and in vivo studies. However, the extent to which AR-mediated 
repression of cyclin D-CDK4/6 complexes remains to be tested in vivo. Similarly, the pro-
apoptotic function of AR has been confirmed by several in vitro studies, but its physiologic role 
in vivo remains untested. Future studies focused on addressing these questions using prostate 
tissue culture together with tissue specific ARKO mice will offer further insights into the 
homeostatic functions of AR signaling in the prostate gland. 
 
Insights for prostate cancer 
In contrast with the anti-proliferative and pro-apoptotic roles of AR in non-malignant 
prostate epithelial cells and a subset of prostate cancer cells, the pro-survival function of AR has 
been more extensively studied. Most prostate cancer cells including castration-resistant prostate 
cancer (CRPC) cells express the AR, and they are somewhat dependent on AR signaling for 
growth and proliferation [126-130,132-136,144,248]. In these cells, pro-survival signaling by 
AR has been suggested to prevent apoptosis through multiple mechanisms, including 
transcriptional up-regulation of CDKN1A/p21[190,244], inhibition of p53 expression and 
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caspase-2 activation [244,250], activation of pro-survival PI3K/AKT signaling [250,252,253], 
and inhibition of BAD through activated MAPK signaling [249,251]. Due to the proliferative 
and pro-survival functions of AR signaling in prostate cancer cells, androgen deprivation therapy 
(ADT) is a first-line treatment for metastatic prostate cancer and the beneficial effects are 
evidenced by rapid and dramatic tumor regression [125,147,254]. However, nearly all prostate 
cancers treated with ADT become resistant to this treatment over a period of months to years, as 
a subset of the malignant cells eventually adapts to survive the ADT-induced environment and 
emerges as CRPC. Whether or not ADT promotes such a transition has recently drawn much 
attention. 
Of note, the onset of the malignancy switch has been suggested to involve two or more 
distinct changes in AR function during prostate tumorigenesis and progression, including a loss 
of AR-mediated growth suppression and a gain of AR-mediated proliferation, making the 
resulting tumor cells dependent of androgen for growth and division [167]. Therefore, the anti-
proliferative and pro-apoptotic functions of AR signaling may be retained in a subset of 
malignant cells in a given tumor. From tumor histology studies, it is well known that prostate 
cancer cells most closely resemble secretory prostate epithelial cells, however recent biomarker 
and genomic studies have revealed that prostate cancers are commonly multifocal and consist of 
heterogeneous cell populations [256,257]. It is reasonable to speculate that distinct populations 
of cells arise, including a population that has become androgen-stimulated for growth and other 
populations that are androgen-independent or androgen-suppressed for growth. The drop of 
serum androgen levels may induce cell cycle inhibition and even death in the androgen-
stimulated population, leading to the initial tumor regression. However, ADT may also loosen 
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the brake imposed on the androgen-suppressed population, in effect providing a selective 
advantage for these cells to survive, proliferate, and support tumor recurrence. 
Recently, it has been shown that both basal and luminal epithelial cells can initiate 
prostate tumors in mouse models [258-261]. In a prostate tissue transformation model, basal 
epithelial cells from benign human prostate tissue that were transduced to overexpress thymoma 
viral proto-oncogene (AKT) and v-myc avian myelocytomatosis viral oncogene homolog (MYC) 
efficiently progressed to adenocarcinoma in immunodeficient mice [260]. Importantly, AR 
expression in benign basal/progenitor cells is known to be low or undetectable, which is 
consistent with AR signaling having anti-proliferative and pro-differentiation roles in normal 
basal/progenitor cells [120]. These results raise the possibility that AR signaling may suppress 
the growth and proliferation of some prostate cancer stem cells. As such, ADT may stimulate the 
proliferation and survival of these cells. Interestingly, it has been reported that AR 
overexpression indeed suppresses the epithelial-mesenchymal transition of prostate cancer stem 
progenitor (S/P) cells isolated from LNCaP. Although the growth and proliferation of non-S/P 
LNCaP cells are androgen-promoted, the activation of AR in S/P cells synergizes with inhibitors 
of AKT signaling to inhibit their proliferation [262]. Although AR-mediated growth suppression 
of S/P cells remains to be confirmed in vivo, our results in HPr-1AR, RWPE-AR, and PC3-Lenti-
AR suggest that developing therapies that selectively inhibit the proliferative and anti-apoptotic 
activities of AR signaling while preserving the anti-proliferative and pro-apoptotic activities may 
provide a beneficial outcome compared to global inhibition of AR signaling. 
 
Conclusions 
In this dissertation, we elucidate novel roles of AR signaling in human prostate epithelial 
cell proliferation and apoptosis, which are tightly regulated processes that influence prostate 
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physiology and function and prostate disease pathology. Under physiologic conditions, AR 
activation suppresses epithelial cell growth and division through transcriptional repression of 
cyclin D-CDK4/6 complexes. As such, AR signaling restrains proliferation and supports 
differentiation in normal/benign adult prostate epithelium. In the response to cellular stress, AR 
activation sensitizes prostate epithelial cells to mitochondrial apoptosis through AR-mediated 
regulation of mitochondrial membrane integrity by transcriptionally shifting BCL2 family gene 
expressions towards a pro-apoptotic direction. As such, pro-apoptotic AR signaling facilitates the 
turnover of stressed and damaged cells and therefore serves as a protective mechanism. Thus, our 
studies have revealed crucial roles of AR signaling in the homeostatic regulation of prostate 
epithelial cell number, which is a crucial determinant of prostate health and prostate disease in 
the aging male.  
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Figures 
 
Fig. 4.1 The homeostatic AR signaling in adult prostate epithelial cells.  
AR functions as a homeostatic signal in normal adult prostate epithelial cells. Under physiologic 
conditions, AR activation suppresses epithelial cell growth and division through transcriptional/post-
transcriptional repression of cyclin D1/2-CDK4/6 complexes. The AR-suppressed growth may serve as a 
differentiation signal in normal adult prostate epithelium. Under stressed conditions, AR signaling is pro-
apoptotic and sensitizes prostate epithelial cells to mitochondrial apoptosis through AR-mediated 
regulation of mitochondrial membrane integrity by transcriptionally inducing pro-apoptotic BCL2 family 
genes (BIM and BOK) and repressing pro-survival BCL2 family genes (BCL-XL and MCL1). The shift 
of balance between pro-apoptotic and pro-survival genes renders mitochondria more vulnerable to 
intrinsic or extrinsic apoptotic stress agents. This pro-apoptotic AR signaling facilitates the turnover of 
stressed cells and hence serves as a protective mechanism. 
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Fig. 4.2 An overview of autophagy and its connection to cell growth and cell death signaling. 
Autophagy plays a crucial role in cellular homeostasis through protein degradation and organelle 
turnover. Upon nutrients deprivation, autophagy is triggered by upstream signals (e.g. AMPK activation 
and mTOR inhibition) to degrade certain regions of cytoplasm to acquire sources of metabolic energy. 
The process of autophagy is proceeded stepwise mediated by multiple autophagy-related gene (ATG) 
complexes. The ULK-ATG13-FIP200 preinitiation complex and Class III PI3K initiation complex 
generates PI3P at the site of nucleation of isolation membrane, leading to recruitment of elongation 
machinery as well as the formation and closure of autophagosome. During the elongation process, the key 
autophagosome marker, LC3-II, is generated from LC3 by ATG4 and then conjugated to the 
autophagosome membrane by a process resembling ubiquitination, which includes ATG7 (E1), ATG3 
and ATG10 (E2), and ATG12-ATG5-ATG16L (E3). Later, autophagosome fuses with lysosome and 
forms autolysosome, which eventually leads to the degradation of its contents. Notably, several ATGs 
(ULK1, ATG12 and ATG4B) are indeed androgen-responsive genes and some of the androgen-repressed 
genes (BCL2 and BCL-XL) are also involved in the regulation of autophagy. These evidences suggest a 
role of AR in the mediation of autophagy. In addition to their functions in the autophagy, ULK1 has also 
been shown to inhibit cell growth and induce mitophagy, whereas ATG12 has been shown to be pro-
apoptotic through the interactions with BCL2, MCL1 and ATG3. Hence, there seem to be an 
interconnection between cell growth, autophagy and cell death pathways. This figure is modified based on 
the current knowledges of autophagy [279].  
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